

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 September 2001 (07.09.2001)

PCT

(10) International Publication Number
WO 01/64713 A2

- (51) International Patent Classification⁷: **C07K 7/00**
- (21) International Application Number: **PCT/EP01/02296**
- (22) International Filing Date: **1 March 2001 (01.03.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
60/186,125 **1 March 2000 (01.03.2000)** **US**
- (71) Applicants and
(72) Inventors: **GASCHE, Christoph [AT/AT]**; Babenberg-
ergasse 20, A-3400 Klosterneuburg (AT). **ZAKERI,**
Schaker, M. [AT/AT]; Einsiedlerplatz 10/19, A-1050
Vienna (AT).
- (72) Inventor; and
(75) Inventor/Applicant (for US only): **REINISCH, Wal-**
ter [AT/AT]; Gumpoldskirchnerstrasse 26/3/17, A-2340
Mödling (AT).
- (74) Agents: **SONN, Helmut et al.**; Riemergasse 14, A-1010
Vienna (AT).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished
upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: **MAMMALIAN INTERLEUKIN-10 (IL-10) RECEPTOR VARIANTS**

	Homozygote Wildtype	Homozygote Variant	Heterozygotes
IL-10RPQ	=====	=====	=====
IL-10RAQ	=====		=====
IL-10RPB		=====	=====

(57) Abstract: Amino acid sequence and nucleic acid encoding variants of the IL-10 receptors, including polymorphisms. Uses of the receptor gene and polypeptides are disclosed, including means for screening for agonists and antagonists of the receptor ligands, for producing diagnostic or therapeutic reagents, and for producing antibodies. Therapeutic or diagnostic reagents and kits are also provided.



WO 01/64713 A2

- 1 -

MAMMALIAN INTERLEUKIN-10 (IL-10) RECEPTOR VARIANTS

Field of the Invention

The present invention relates generally to nucleic acids and polypeptides characteristic of variants of receptors for mammalian interleukin-10 (IL-10). These variants preferably display at least 3 fold modified, e.g., greater, response to ligand binding than a reported receptor. The present invention also describes a single nucleotide polymorphism in the genomic sequence of the receptor that cause an incorrect splicing of the pre-mRNA and produce an aberrant mRNA which leads to a truncated and mutated form of the receptor. More particularly, this invention embraces use of variant receptors in preparing reagents useful for diagnosing or treating various IL-10 or receptor-related medical conditions.

BACKGROUND OF THE INVENTION

The proliferation, differentiation, and effector function of immune cells are regulated by a complex network of interactions. Although many of these processes involve cell-cell contact, most are mediated wholly or in part by the cytokines, a family of proteins secreted by activated hemopoietic cells. See Ho, et al. (1994) *Ther. Immunol.* 1:173-185. Most cytokines have more than one biological activity. The activity which is regarded as the most important likely depends on the local context in which the cytokine is produced.

As soluble intercellular messenger molecules, the cytokines typically bind to cellular receptors, e.g., cell surface receptors. Receptor molecules have been identified and isolated for G-CSF, GM-CSF, EPO, TNF, IFN-gamma, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, and many others. See, e.g., Gearing, et al. (1989) *EMBO J.* 8:3667-3676 (low affinity alpha chain of the human GM-CSF receptor); Itoh, et al. (1990) *Science* 247:324-327 (low affinity alpha chain of a mouse IL-3 receptor); Hayashida, et al. (1990) *Proc. Natl Acad. Sci.* 87:9655-9659 (a beta chain of a human GM-CSF receptor); Tavernier, et al. (1991) *Cell* 66:1175-84 (IL-5 receptor, alpha and beta chains); Silvennoinen and Ihle (1996) *Signaling by the Hematopoietic Cytokine Receptors* (ISBN: 041210881X); and Nicola (Ed. 1995) *Guidebook to Cytokines and Their Receptors* Oxford Univ. Press (ISBN: 0198599471). Many of these receptors have two chains, both of which are members of the hemopoietic receptor su-

- 2 -

perfamily. In such cases, typically one chain, designated the alpha chain, can bind its ligand with low affinity which may or may not result in transduction to the cell of a signal. Following the binding of a ligand to the alpha chain, another chain, designated the beta chain, is recruited and associates with the alpha chain. This interaction confers higher affinity binding of the heterodimeric receptor to the cytokine. See Miyajima, et al. (1992) *Ann. Rev. Immunol.* 295-331. The beta chain by itself usually lacks significant ligand binding affinity. The dimeric form of receptor is capable of transducing a signal into the cell as a consequence of ligand, e.g., cytokine, binding. Additional subunits or accessory proteins may also be associated with the receptors.

The various components of the earlier identified receptors appear to share properties useful in defining a receptor superfamily of related proteins. See Bazan (1990) *Immunology Today* 11:350-354; and Bazan (1990) *Proc. Natl. Acad. Sci. USA* 87:6934-6938. However, the structure and mechanism of action of a receptor for a mammalian interleukin-10 (IL-10) could not be predicted with reliability based merely upon speculated similarity to receptors for other cytokines.

A cytokine synthesis inhibitory factor (CSIF) activity led to assays which allowed the isolation of a cytokine designated interleukin-10 (IL-10). See Fiorentino, et al. (1989) *J. Exp. Med.* 170:2081-2095; and Mosmann, et al. (1991) *Immunol. Today* 12:A49-A53. Both mouse and human counterparts have been isolated. See Moore, et al. (1990) *Science* 248:1230-1234; and Vieira, et al. (1991) *Proc. Nat'l Acad. Sci. USA* 88:1172-1176. A human viral analog, known as either vIL-10 or BCRF1, has been described which shares many characteristic activities of the natural human form. See Hsu, et al. (1990) *Science* 250:830-832. Another viral homologue has been described from an equine herpes virus. See Rode, et al. (1993) *Virus Genes* 7:111-117.

Interleukin-10 (IL-10) inhibits cytokine synthesis by activated T cells, stimulates growth for thymocytes and mast cells, induces class II MHC expression, and sustains viability in culture of small dense resting mouse B cells (de Waal et al., 1992). Because of its inhibition of TNF production and suppression of a TH1 immune response, IL-10 has been considered as a key model for anti-inflammatory cytokines (Moore et al., 1993). Two viral IL-

- 3 -

10 homologues had also been identified that take advantage of the host's anti-inflammatory IL-10 signaling pathway (Liu et al., 1997a; Kotenko et al., 2000). As with other cytokines, the biological effects of IL-10 are mediated through cell-surface receptors. Human and mouse receptor subunits for IL-10 have been identified and found to be members of the interferon receptor-like subgroup of the cytokine receptor family (Tan et al., 1993; Ho et al., 1993; Liu et al., 1994). Functionally active IL-10 receptors are composed of two distinct subunits. The IL-10RA is a 110-kDa polypeptide and plays a dominant role in mediating high affinity ligand binding and signal transduction. The IL-10 receptor beta subunit (IL-10RB; also known as CRF2-4) is predicted to be a 40-kDa protein that is largely required only for signaling (Spencer et al., 1998; Kotenko et al., 1997). The human IL-10RA gene was mapped to chromosome 11q23 (Liu et al., 1994). Interaction of IL-10 with its receptors stabilizes dimerisation of both IL-10R subunits, and activates phosphorylation of the receptor-associated Janus tyrosine kinases, JAK1 and Tyk2 (Stahl et al., 1995). These kinases then phosphorylate specific tyrosine residues (Y446 and Y496) on the intracellular domain of the IL-10RA. Once phosphorylated, these tyrosine residues and their flanking peptide sequences serve as temporary docking sites for the latent transcription factors, STAT1, STAT3, and in some cells also STAT5 (signal transducer and activator of transcription) (Darnell, Jr., 1997; Donnelly et al., 1999). STAT3 binds to these sites via its SH2 (Src homology 2) domain, and is, in turn, tyrosine-phosphorylated by the receptor-associated JAKs (Ullrich and Schlessinger, 1990). It then homodimerizes and translocates to the nucleus where it binds with high affinity to STAT-binding elements (SBE) in the promoters of various IL-10-responsive genes. One of these genes, SOCS-3 (Suppressor of Cytokine Signaling-3) is a member of a newly identified family of genes that inhibit JAK-STAT-dependent signaling. Studies in mice with disrupted genes for JAK1 or STAT1 have revealed that the anti-inflammatory action of IL-10 is dependent on JAK1 but does not necessarily require the presence of STAT1 (Meraz et al., 1996; Rodig et al., 1998). Serine residues of the IL-10RA (i.e. those at positions 541, 544, 553 and 554) at the carboxyl-terminal region of the murine IL-10RA are also required for inhibition of TNF-alpha production in macrophages. Thus, an accessory signal

- 4 -

pathway to the JAK1-STAT3 is required for expression of the anti-inflammatory actions of IL-10 (Riley et al., 1999). In contrast, the IL-10 mediated proliferation of Ba/F3 cells and activation of STAT3 is not altered by displacement of the serine residues. Indeed, STAT3 and JAK1 are central in IL-10R signaling, but not sufficient in mediating the complete repertoire of anti-inflammatory IL-10 action.

The relationship between the structure and the function of the IL-10 receptor remains incompletely understood. In order to increase the functional understanding of different receptor domains, Ho et al. created cytoplasmic receptor variants (Ho et al., 1995). Two distinct functional regions near the C-terminus of the murine IL-10RA were identified to mediate proliferation; one of these regions also mediates the differentiation response. Deletion of a third region proximal to the transmembrane domain (Aa 282-389) renders the cells 30- to 100-fold more sensitive to IL-10. The deletion mutant receptor (del 282-389) was regarded as a superactivating receptor. This deletion variant may be useful in altering the response to intervention by IL-10.

Targeted disruption of the IL-10 gene in mice causes chronic intestinal inflammation similar to human inflammatory bowel diseases (IBD, referring to both Crohn's disease and ulcerative colitis) (Kuhn et al., 1993). Silencing of other genes of the IL-10 signaling pathway showed similar intestinal inflammatory responses (Spencer et al., 1998; Takeda et al., 1999). IL-10 was shown to downregulate the enhanced protein secretion of proinflammatory cytokines in activated intestinal macrophages (Schreiber et al., 1995). A general IBD-specific alteration of the IL-10 pathway was, however, not found in human IBD subjects (Gasche et al., 2000a). The phenotypic appearance of Crohn's disease is, however, heterogenous (Gasche et al., 2000b), the genetic trait is complex, and various loci had been linked to disease susceptibility (Hugot et al., 1996; Satsangi et al., 1996; Cho et al., 1998; Hampe et al., 1999; Rioux et al., 2000). This indicates that possible genetic alterations in the IL-10 pathway in IBD may have been covered in those studies by the vast majority of IBD patients who has no genetic alteration in the IL-10 pathway.

In parallel to these investigations, the efficacy of IL-10 was tested for the treatment of IBD, specifically active Crohn's disease (Van Deventer et al., 1997; Fedorak et al., 2000; Schrei-

- 5 -

ber et al., 2000). The trials showed that IL-10 therapy was effective in up to 30 percent of patients, and induced persistent healing of ulcerated intestinal mucosa in some cases. These findings were remarkable, because no such endoscopic improvement was found in the placebo treated patients. Moreover, steroids, which are still regarded as the standard drug for the treatment of active Crohn's disease, do not change the degree of intestinal inflammation (Modigliani et al., 1990).

Preclinical and clinical data suggests evidence that recombinant IL-10 may be useful in the treatment of chronic hepatitis C and other chronic liver diseases that may eventually cause fibrosis and cirrhosis (Nelson, et al (2000) Gastroenterology 118: 655-660; Arai, et al (1995) J Immunol 155:5743-5749; Louis, et al (1997) Hepatology 25:1382-89).

Using SSCP analysis, Japanese investigators had identified two silent SNPs within the IL-10RA coding region (G241A and G520A do not alter the IL-10RA amino acid sequence) (Tanaka et al., 1997).

Such variants, particularly natural polymorphic forms, will also be useful to characterize regions which mediate different responses of ligand binding or to identify patient populations, e.g., polymorphic variants, which may be more or less susceptible to therapeutic intervention. The present invention provides these and the means of preparing many useful reagents.

SUMMARY OF THE INVENTION

The present invention is based in part on the surprising result that certain polymorphic variants of a "standard" wild-type mammalian IL-10 receptor can be made which are differentially sensitive to a ligand, i.e., providing a higher (or lower) signaling response upon the presence of specific amounts of ligand, than the wild-type "standard" counterpart. In particular, sites of the receptor have been identified which, upon modification, result in a differentially active receptor. As potential critical residues, these residue positions are likely able to alternatively decrease responsiveness. Here, substitution variants are identified leading to a functional phenotype.

One embodiment includes, e.g., an isolated or recombinant polypeptide comprising a sequence substitution at position gly351 and/or ser159 (according to Seq.ID No.2) or from position 62

- 6 -

(e.g. in Seq.ID No.5; i.e. wherein leu62 is wild type and arg63 is the first amino acid from the substituted further sequence) of standard human IL-10 receptor subunit alpha (IL-10RA). In various embodiments, the substitution of gly is with a charged amino acid; the substitution of ser is with an uncharged amino acid; the polypeptide effects at least a three fold change in signal from IL-10 binding; the substitution of gly is with arginine (especially the substitution of the AGC codon (nucleotides 475 to 477 according to Seq.ID No. 1) (preferably to GGC)); the substitution of ser is with gly (especially the substitution of the GGG codon (nucleotides 1051 to 1053 according to Seq.ID No. 1) (preferably to AGG)); or the change is an increase. Preferred embodiments of the variant polypeptides according to the present invention are the processed forms of these variant IL-10RA polypeptides, especially forms lacking the 21 amino acid long N-terminal signal sequence (see: e.g. GeneBank entry U00672).

Other embodiments include methods of making an antibody which can distinguish the IL-10RA polypeptide variant from the corresponding polypeptide of standard human IL-10RA, comprising immunizing a mammal with the variant, thereby producing an antibody which recognizes the variant but not the standard IL-10RA, e.g., comprising expressing an isolated or recombinant nucleic acid encoding the variant polypeptide. Thus, the invention also provides an isolated or recombinant nucleic acid encoding the variant polypeptide, and a cell transformed with the isolated nucleic acid.

Alternatively, the invention provides an isolated or recombinant IL-10RA polypeptide of at least 12 amino acids comprising at least three residues matching each side of and flanking a substitution of gly351 or ser159 or from position 63 of standard human IL-10RA. Preferred embodiments include, e.g., wherein the: substitution of gly351 of standard human IL-10RA is a superactivating IL-10RA; substitution is G351R or S159G; polypeptide matches at least 5 residues on each side flanking gly351 or ser159; substitution of IL-10RA effects at least a three fold change in signal from IL-10 binding; polypeptide comprising a sequence of TLGNREPPV or DTYESIFSH; or change is an increase. Similarly, the invention provides methods of making a polypeptide comprising expressing a nucleic acid encoding the polypeptide. Such an isolated or recombinant nucleic acid encoding the recom-

- 7 -

binant polypeptide is also provided, including, e.g., a nucleic acid further encoding other portions of the IL-10RA, e.g.,: the extracellular domain of IL-10RA; the intracellular domain of IL-10RA; N proximal sequence from S159 of IL-10RA; or C proximal sequence from G351 of IL-10RA. Also embraced is a cell transformed with the nucleic acid.

Another embodiment of the present invention relates to a substitution from position 63 onwards, i.e. leu62 being according to the human wild type sequence, the further amino acids being truncated or at least partially substituted by other amino acids, especially according to Seq.ID. No. 5. A preferred deletion relates to a polypeptide encoded by a nucleotide sequence comprising the coding sequence for standard human IL-10RA, wherein nucleotides after position 189 in Seq.ID No 1 are replaced by an alternative sequence, e.g. as defined in Seq.ID No.4.

The invention also provides methods of making an antibody which can distinguish the IL-10RA variant polypeptide from the corresponding polypeptide of standard human IL-10RA, comprising immunizing a mammal with the variant, thereby producing an antibody which can distinguish. The antibody will typically be capable of distinguishing a variant polypeptide from the corresponding polypeptide of standard human IL-10RA. In various forms, the antibody is: a polyclonal antibody preparation; an immunoselected antibody preparation; an immunodepleted antibody preparation; or a monoclonal antibody.

The invention further provides methods allowing distinguishing: a nucleic acid encoding the variant from one encoding standard human IL-10RA, the method comprising comparing the nucleic acid to one encoding the standard human IL-10RA; or a polypeptide variant from standard human IL-10RA, the method comprising comparing the polypeptides. Nucleic acid sequence used herein refers to an oligonucleotide, nucleotide or polynucleotide, and fragments or portions thereof, and DNA and RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand. Similarly, amino acid sequence as used herein refers to peptide or protein sequence. In certain embodiments, the comparing is: of nucleic acids, and the comparing is of: PCR products; or restriction fragments; or hybridization assays with oligo- or polynucleotides or derivatives thereof which provide selective discrimination or of polypep-

- 8 -

tides, and the comparing is by: immunoassay; or evaluating cell responsiveness to IL-10. In preferred embodiments, the distinguishing: allows therapeutic prognosis; provides differential function information on said respective variants; or determines therapeutic treatment.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

OUTLINE

- I. General
- II. Receptor Variants
- III. Nucleic Acids
- IV. Making Receptor
- V. Receptor Isolation
- VI. Receptor Analogs
- VII. Antibodies
- VIII. Other Uses of Receptors
- IX. Ligands: Agonists and Antagonists
- X. Kits
- XI. Therapeutic Applications
- XII. Additional Receptor Subunits

I. General

Genetic factors appear to contribute to virtually every human disease, conferring susceptibility or resistance, affecting the severity or progression of disease, and interacting with environmental influences. Much of current biomedical research, in both the public and private sectors, is based upon the expectation that understanding the genetic contribution to disease will revolutionize diagnosis, treatment, and prevention. Defining and understanding the role played by genetic factors in disease will also allow the non-genetic, environmental influences on disease to be more clearly identified and understood.

Analysis of DNA sequence variation is becoming an increasingly important source of information for identifying the genes involved in both disease and in normal biological processes. In trying to understand disease processes, information about genetic variation is critical for understanding how genes function or

- 9 -

malfunction, and for understanding how genetic and functional variations are related. Response to therapies can also be affected by genetic differences. Information about DNA sequence variation will thus have a wide range of application in the analysis of disease and in the development of diagnostic, therapeutic, and preventative strategies.

A key aspect of research in genetics is associating sequence variations with heritable phenotypes. There are several types of DNA sequence variation, including insertions and deletions, differences in the copy number of repeated sequences, and single base pair differences. The latter are the most common. They are termed single nucleotide polymorphisms (SNPs) when the variant sequence type has a frequency of at least 1% in the population. SNPs occur approximately once every 100 to 1000 bases. Because SNPs are expected to facilitate large-scale genetic association studies, there has recently been great interest in SNP discovery and detection (Halushka et al., 1999; Irizarry et al., 2000). Important examples of disease associations with SNPs are known, including the APOE*E4 allele (apolipoprotein E epsilon 4) in late-onset familial and sporadic Alzheimer disease (Saunders et al., 1993), the F5 1691G>A allele (also known as factor V Leiden) in deep-venous thrombosis (Bertina et al., 1994), and the CKR5D32 (chemokine receptor 5) in resistance to HIV infection (Dean et al., 1996).

Different classes of polymorphisms are considered according to their sites within genes (non-coding, degenerate and non-degenerate sites). The coding-region SNPs (that have recently been termed cSNPs), which alter the amino acid sequence of the encoded protein, are most likely to influence disease and are found at lower rates and with lower allele frequencies than silent substitutions (Cargill et al., 1999). This likely reflects selection against harmful alleles during human evolution. Such nucleotide sequence variations may cause functional changes of the encoded proteins and could lead to disease development. It is also undoubtedly the case that some of the SNPs in non-coding DNA will also have functional consequences, such as those in sequences that regulate gene expression (Eskdale and Gallagher, 1995; Eskdale et al., 1998). Discovery of SNPs that affect biological function will become increasingly important over the next several years. From the large scale of SNPs in human DNA, those, which

- 10 -

render functional significance, need to be selected. Accordingly, a better understanding of the functional changes of SNPs, specifically of cSNPs, will help to better understand how genes function or malfunction. In addition, the response to therapies can be affected by such genetic differences. In fact, this is the very objective of our research proposal with regard to newly identified cSNPs on the Interleukin-10 receptor alpha (IL-10RA).

Standard methods for mutation detection include such as PCR amplification of specific alleles, multiplex PCR; oligonucleotide ligation assay, restriction fragments length polymorphism, single strand conformation polymorphism, heteroduplex analysis assays, allele specific hybridization, etc. and sequencing methods such as mini sequencing, sequencing by hybridization, allele specific nucleotide incorporation such as pyrosequencing (Pyrosequencing AG, Uppsala, Sweden), or such as TaqMan® genotyping assay (Applied Biosystems, Foster City, CA) and molecular beacon genotyping, strand displacement amplification assays, rolling circle amplifications methods, Invader Assay (Third Wave Technologies, Inc. Madison, WI) and fluorescent microarray-based methods (eg. from Affymetrix Inc., CA) and automated enzyme-linked immunoabsorbant assays (eg. Orchid BioScience Inc., Princeton, NJ) and mass spectrometry genotyping technologies (eg. from Sequenom, San Diego, CA and Hamburg, Germany or Masscode™ system from Qiagen Genomics Inc.) and such as small DNA biochips containing electronically active electrodes coated with specific DNA probe such e-sensor™ system (Motorola's Clinical Micro Sensor Technology division, Pasadena, CA) or using NanoChip™ system (Nanogen, San Diego, CA) etc, eg. in Cotton (1997) Mutation detection, Oxford University Press; Hawkins, et al (1997) Finding Mutations, The Basics IRL Press at Oxford University Press, Hirschhorn et al (2000) Proc. Natl Acad Sci USA; 97(22):12164-12169; Schweitzer, et la (2001) Curr Opin Biotechnol.;12(1):21-27, Shi, (2001) Clin Chem. 47(2):164-172; all of which are incorporated herein as reference. Standard optimization guidelines for PCR; multiplex PCR, refinement of primer design parameters etc., are described or referenced eg. in Innis; et al (1999) PCR Applications, Protocols for functional genomics, Academic Press.

Other novel methods for SNP detection to be used within the present invention are e.g.: Sapolsky et al. (1999) US Pat No. 5,858,659; Shuber (1997) US Pat No. 5,663,134; Dahlberg (1998) US

- 11 -

Pat 5,719,028; Murigneux (1998) WO98/30717; Shuber (1997) WO97/10366; Murphy et al (1998) WO98/44157; Lander et al. (1998) WO98/20165; Goelet et al. (1995) WO95/12607 and Cronin et al (1998) WO98/30883. In addition Ligase base methods described by Barany et al (1997) WO97/31256 and Chen et al. Genome Res. 1998; 8(5):549-56; mass-spectroscopy-based methods by Monforte (1998) WO98/12355, Turano et al. (1998) WO98/14616 and Ross et al. (1997) Anal. Chem. 15, 4197-202; PCR-based methods by Hauser et al (1998) Plant J. 16, 117-25; exonuclease based methods by Mundy US Pat No. 4,656,127; dideoxy-based methods by Cohen et al. WO91/02087, Genetic Bit Analysis or GBA™ by Goelet et al WO92/15712; Oligonucleotide Ligation Assays or OLA by Landegren et al. (1988) Science 241:1077-1080 and Nickerson et al. (1990) Proc. Natl. Acad. Sci. (U.S.A.) 87:8923-8927; and primer guided nucleotide incorporation procedures by Prezant et al. (1992) Hum. Mutat. 1:159-164; Ugozzoli et al. (1992) GATA 9: 107-112; Nyréen et al. 1993 Anal. Biochem. 208:171-175.

The present invention relates to differentially activating IL-10 receptor (IL-10R) proteins and nucleic acids (see SEQ ID NO: 1-4) and antibodies. Differentially, e.g., super, activating receptors from other mammals, e.g., mouse, rat, pig, sheep, goat, etc., are also contemplated. This application hereby incorporates by reference USSN 08/110,683, filed on August 23, 1993; and USSN 08/424,788, filed on April 19, 1995.

Ba/F3 cells expressing recombinant IL-10R (BaF-mIL-10R) subunit alpha (also designated IL-10RA) exhibit a proliferative response to IL-10, whereas the parent Ba/F3 cells do not. See Ho, et al. (1993) Proc. Natl. Acad. Sci. USA 90:11267-11271; Liu, et al. (1994) J. Immunol. 152:1821-1829; USSN 08/110,683; USSN 08/011,066; and USSN 07/989,792. Both mIL-10 and hIL-10 stimulate BaF-mIL-10R (BaMR29a1) cells with similar specific activities of 0.5-1 x 10⁷ unit/mg, similar to that observed for the macrophage deactivating factor/CSIF activity of IL-10. See Fiorentino, et al. (1989) J. Exp. Med. 170:2081-2095; Ho, et al. (1994) Therapeutic Immunology 1:173-185; and Moore, et al. (1993) Ann. Rev. Immunol. 11:165-190. See also USSN 08/110,683 and USSN 08/424,788, each of which is incorporated herein by reference.

Mutant mIL-10R containing various deletions of the cytoplasmic domain were prepared and stably expressed in Ba/F3 cells, along with individual tyrosine to phenylalanine (Y->F) mutations

- 12 -

of the four tyrosines (Y374F, Y396F, Y427F, and Y477F) in the cytoplasmic domain of the mature mouse IL-10R polypeptide. See Ho, et al. (1993) Proc. Natl. Acad. Sci. USA 90:11267-11271; and US Pat. 5,716,804. Two independent DNA clone isolates and their stable transfectants were characterized for each mutant. Ba/F3 transfectants stably expressing mutant IL-10R were tested for induction of proliferation by IL-10.

Ba/F3 transfectants expressing membrane-proximal variations, e.g., deletion mutations del282-389, del282-414, and del282-458, display a striking and unexpected property of a 1.5-2 log greater proliferative response to IL-10 compared to "standard" or wild-type human IL-10R (see USSN 08/110,683; note that the numeric referencing applied in the deletional studies refer to the mature sequence, with signal removed) and are thus termed "super-activating" variants. This property is not due to a significantly increased IL-10R expression level or binding affinity for IL-10, since these variant IL-10R exhibit ligand binding properties similar to both a non-super-activating variant (del483-559) and wild-type mIL-10R. In fact, K_d values for the mutant mIL-10R (400-600 pM) are somewhat higher than the wild type. See Ho, et al. (1993) Proc. Natl. Acad. Sci. USA 90:11267-11271; Tan, et al. (1993) J. Biol. Chem. 268:21053-21059; USSN 08/110,683; USSN 08/011,066; and USSN 07/989,792. Super-activation is probably not due to impaired IL-10R internalization, since mIL-10R del282-389 and del282-458 internalize 125I-hIL-10 at least as proficiently as wild-type mIL-10R, and actually better than the non-super-activating del433-559 mutant. These deletions define residues which may be generally important, e.g., in interactions with a suppressor factor, and those interactions may mediate functional differences also.

Two papers report natural polymorphic variations of human IL-10 receptor subunit alpha (IL-10RA). See Nakashima, et al. (1999) Rheumatology 38:1142-1144 (reporting G241A and G520A variants); and Tanaka, et al. (1997) Immunogenetics 46:439-441 (reporting silent variations). None of those have been identified as functionally different variations.

The super-activating receptors may lack a structure or domain which affects a self-inhibiting pathway in IL-10 signaling. There is evidence in IL-3R and EPO-R that there are cytoplasmic regions which, upon phosphorylation, normally downregulate re-

- 13 -

sponses to ligand binding. See D'Andrea, et al. (1991) Mol. Cell. Biol. 11:1980-1987; Sakamaki, et al. (1992) EMBO J. 11:3541-3549; and Sato, et al. (1993) EMBO J. 12:4181-4189.

Sensitivity describes an ability to induce proliferation, or other signaling readout, of a target cell expressing the different activating receptor. The present invention contemplates receptors with modified sensitivity, e.g., exhibiting a sensitivity of at least about 2-fold different than a wild-type receptor, generally at least about 4-fold, often at least about 7-fold, typically at least about 10-fold, usually at least about 13-fold, preferably at least about 20-fold, and in particular embodiments, at least about 30-fold or more change, e.g., increase or decrease, in sensitivity.

The described polymorphisms are analysed for differences in signal transduction, both with respect to quantity, e.g., strength of each effector signal, as well as quality of signal, or combination of effector functions. Thus, certain polymorphisms may lead to different changes in one effector function relative to another.

Super-activating receptors will be useful for testing a sample for the presence of a ligand, e.g., human IL-10 or analogs thereof, in a sample. Gene therapy indications may allow for cells more sensitive to lower doses of ligand. Kits exhibiting extremely high sensitivity are also contemplated for diagnostic purposes, including determination of patient subsets who may be more responsive to ligand, and susceptible to successful treatment. Conversely, less sensitive receptors may be similarly useful, e.g., in studying ligand-receptor interactions or for diagnosis of patients.

II. Receptor Variants

Isolated DNA encoding "standard" receptors can be readily modified, e.g., by nucleotide substitutions. Receptor variants can also be produced by either genetic engineering methods or protein synthesis techniques. See, e.g., USSN 08/110,683; USSN 08/011,066; USSN 07/989,792; Sambrook, et al. (1989); Ausubel, et al. (1987 and supplements); Cunningham, et al. (1989) Science 243:1330-1336; O'Dowd, et al. (1988) J. Biol. Chem. 263:15985-15992; Beaucage and Caruthers (1981) Tetra. Letts. 22:1859-1862; and Lechleiter, et al. (1990) EMBO J. 9:4381-4390; each of which

- 14 -

is incorporated by reference. Additional methods will be apparent to a person having ordinary skill in the art in light of the teaching provided herein.

The IL-10RA G351R (numbered relative to the open reading frame, including signal sequence; corresponding to residue 330 of mature receptor) is located in the middle of a region (aa 282-389) which, when deleted in mice (del282-389), results in a superactivating receptor with a 30 to 100 fold increase in sensitivity to IL-10. Ho, et al. (1995) Mol. Cell. Biol. 15:5043-5053. The substitution of a neutral and polar amino acid (glycine) by a basic amino acid (arginine) in this sensitive part of the receptor could cause a change in receptor function. The allele contains a substitution of nucleotide 1051 G to A, resulting in the amino acid residue substitution, which correlates with therapeutic responsiveness in the inflammatory bowel disease studies described below. The IL-10RA G351R SNP might interfere with receptor dimerization, internalization, degradation, activation of the Jak/STAT signaling pathway, or with its negative regulation by cytokine-inducible SH2 (CIS) proteins. These potential receptor alterations could explain why patients expressing at least one IL-10RA G351R allele show a favorable response to rhIL-10. Another natural polymorphism appears to be at residue ser159, resulting from a substitution of nucleotide 475 A to G and after residue leu62, resulting from an aberrantly spliced form due to a G to A substitution in the acceptor site of the exon in the intron-exon boundary at position 255 of the genomic fragment Seq.ID No.3. Other natural variations have been identified, the G351R correlates with modified function.

Studies are possible to address some of the hypothesized modifications of receptor function. By altering the receptor sensitivity to autologous IL-10, these SNPs might also be involved in the genetic susceptibility to various diseases. Examples include inflammatory bowel diseases, autoimmune diseases, chronic graft-versus-host diseases, atopic disorders, sepsis, and lymphoproliferative tumors. This latter hypothesis will be addressed below.

III. Nucleic Acids

This invention contemplates use of isolated nucleic acids, e.g., DNA, which encode these different activating receptor com-

- 15 -

ponents for IL-10-like ligands, e.g., peptides. Also included are substantially homologous sequences or fragments thereof. As indicated above, specific embodiments have demonstrated that deletion of regions 282-389, 282-414, and 282-458 of mouse IL-10R result in the super-activating phenotype, and the G351R variation of human receptor probably has the same effect. This suggests that this phenotype may be correlated with other variations in these regions, particularly in the region of 282-389. Corresponding variations in species or allelic variants should also exhibit similar properties. General descriptions of nucleic acids, their manipulation, and their uses are provided in the following references: USSN 08/110,683; USSN 08/011,066; USSN 07/989,792; Kanehisa (1984) Nuc. Acids Res. 12:203-213; Wetmur and Davidson (1968) J. Mol. Biol. 31:349-370; Goodnow (1992) "Transgenic Animals" in Roitt (ed.) Encyclopedia of Immunology Academic Press, San Diego, pp. 1502-1504; Travis (1992) Science 256:1392-1394; Kuhn, et al. (1991) Science 254:707-710; Capecchi (1989) Science 244:1288; Robertson (1987) (ed.) Teratocarcinomas and Embryonic Stem Cells: A Practical Approach IRL Press, Oxford; and Rosenberg (1992) J. Clin. Oncol. 10:180-99; each of which are incorporated by reference. Additional aspects will be apparent to a person having ordinary skill in the art in light of the teachings provided herein.

In particular, the present invention suggests that analysis of specific IL-10RA sequences may identify additional functional variants, including natural polymorphisms, as well as provide means to perform structure-function analysis. PCR or other means to study the specific sequences of the gene will be useful.

IV. Making Receptor

A DNA encoding a different activating IL-10 receptor is available by mutagenesis of a standard human IL-10 receptor available, e.g., in pSW8.1 (ATCC Deposit No. 69146) and USSN 08/110,683. The DNA can be expressed in a wide variety of expression systems as described in, e.g., USSN 08/110,683; USSN 08/011,066; USSN 07/989,792; Pouwels, et al. (1985 and supplements) Cloning Vectors: A Laboratory Manual, Elsevier, N.Y.; Rodriguez, et al. (1988) (eds.) Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Butterworths, Boston; Brosius, et al. (1988) "Expression Vectors Employing Lambda-, trp-, lac-, and

- 16 -

Ipp-derived Promoters", in Vectors: A Survey of Molecular Cloning Vectors and Their Uses, (eds. Rodriguez and Denhardt) Butterworths, Boston, Chapter 10, pp. 205-236; Okayama, et al. (19885) Mol. Cell Biol. 5:1136-1142; Thomas, et al. (1987) Cell 51:503-512; and O'Reilly, et al. (1992) Baculovirus Expression Vectors: A Laboratory Manual, Freeman & Co., N.Y.; each of which is incorporated by reference. It will be appreciated by those skilled in the art that a result of degeneracy of the genetic code, a multitude of IL-10RA-encoding nucleotide sequences, some bearing minimal homology to the nucleotide sequence of any known naturally occurring may be produced. The invention contemplates each and every possible variation of nucleotide sequence that could be made in accordance with the standard triplet genetic code as applied to the nucleotide sequence encoding the naturally occurring IL-10RA variants considered to be specifically disclosed. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding the IL-10RA variants include the production of RNA transcripts having more desirable properties, such as greater half-life, than transcripts having from the naturally occurring sequence. Additional teachings will be apparent to a person having ordinary skill in the art in light of the teachings provided herein.

V. Receptor Isolation

The DNA described above will be useful in producing high levels of receptor materials. Many of the uses will not require purification of the materials as their expression on cells will often be sufficient. However, these expressed receptors can be purified as described in, e.g., USSN 08/110,683; USSN 08/011,066; USSN 07/989,792; Hochuli (1989) Chemische Industrie 12:69-70; Hochuli (1990) "Purification of Recombinant Proteins with Metal Chelate Adsorbent" in Setlow (ed.) Genetic Engineering, Principle and Methods 12:87-98, Plenum Press, N.Y.; Crowe, et al. (1992) QIAexpress: The High Level Expression & Protein Purification System QUIAGEN, Inc., Chatsworth, CA; Ausubel, et al. (eds.) (1987) Current Protocols in Molecular Biology; Deutscher (1990) "Guide to Protein Purification" in Meth. Enzymol., Vol. 182, and other

- 17 -

volumes in series; and manufacturers' literature on use of protein purification products, e.g., Pharmacia, Piscataway, N.J., or Bio-Rad, Richmond CA; each of which is incorporated by reference. Additional methods will be apparent to a person having ordinary skill in the art in light of the teachings provided herein.

VI. Receptor Analogs

Derivatives of naturally occurring different activating receptors are also encompassed by the present invention, particularly those exhibiting a feature of substantially different, e.g., increased, proliferative response to IL-10 ligand binding relative to a natural receptor. These derivatives include sequence variants, glycosylation variants, and covalent or aggregative conjugates with other chemical moieties. See, e.g., USSN 08/110,683; USSN 08/011,066; USSN 07/989,792; Godowski, et al. (1988) *Science* 241:812-816; Beaucage and Caruthers (1981) *Tetrahedron Letts.* 22:1859-1862; Sambrook, et al. (1989) *Molecular Cloning: A Laboratory Manual* (2d ed.), Vols. 1-3, Cold Spring Harbor Laboratory; Merrifield (1963) *J. Amer. Chem. Soc.* 85:2149-2156; Merrifield (1986) *Science* 232: 341-347; Atherton, et al. (1989) *Solid Phase Peptide Synthesis: A Practical Approach*, IRL Press, Oxford; von Heijne (1992) *J. Mol. Biol.* 225:487-494; and Fasman, et al. (1990) *Trends in Biochemical Sciences* 15:89-92; each of which is incorporated by reference. Additional methods will be apparent to a person having ordinary skill in the art in light of the teachings provided herein.

VII. Antibodies

Various types of antibodies and antibody binding compositions can be raised to epitopes on different activating receptors, particularly those which may distinguish a different activating variant from "standard" natural form. For example, specific antigenic peptides with variant sequences in the designated region will present epitopes distinct from the "standard" sequence, e.g., as described in USSN 08/110,683. See also, e.g., USSN 08/011,066; USSN 07/989,792; Microbiology, Hoeber Medical Division, Harper and Row, 1969; Landsteiner (1962) *Specificity of Serological Reactions*, Dover Publications, New York; Williams, et al. (1967) *Methods in Immunology and Immunochemistry*, Vol. 1, Academic Press, N.Y.; Stites, et al. (eds.) *Basic and Clinical*

- 18 -

Immunology (4th ed.), Lange Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane (1988) Antibodies: A Laboratory Manual, CSH Press; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed.) Academic Press, N.Y.; Kohler and Milstein (1975) in Nature 256: 495-497; Huse, et al. (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science 246:1275-1281; Ward, et al. (1989) Nature 341:544-546; U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; 4,366,241; and Cabilly, U.S. Patent No. 4,816,567; each of which is incorporated by reference. Additional methods will be apparent to a person having ordinary skill in the art in light of the teachings provided herein.

VIII. Other Uses of Receptors

Different activating receptors or fragments thereof will have many other uses, e.g., as carriers for a ligand, agonist, or antagonists; means to isolate other subunits of the receptor; in diagnostic assays; or as reagents for structural determination of critical residues in various interactions with hypothesized inhibitory interactions. See, e.g., USSN 08/110,683; USSN 08/011,066; USSN 07/989,792; Hayashida, et al. (1990) Proc. Natl Acad. Sci. USA 87:9655-9659; Fodor, et al. (1991) Science 251:767-773; Parce, et al. (1989) Science 246:243-247; Owicki, et al. (1990) Proc. Nat'l Acad. Sci. USA 87:4007-4011; Lowenstein, et al. (1992) Cell 70:705-707; and Blundell and Johnson (1976) Protein Crystallography, Academic Press, N.Y. Diagnostic measurements other than proliferation are also contemplated, e.g., inhibition of cytokine production or induction of antigen expression. Assays include those which detect induction of transcription factors and/or DNA binding proteins, e.g., stat1 or p91. See, e.g., Pearse, et al. (1991) Proc. Natl. Acad. Sci. USA 88:11305-11309; and Pearse, et al. (1993) Proc. Natl. Acad. Sci. USA 90:4314-4318. Also contemplated are assays for molecules involved in signal transduction, e.g., phosphorylation of tyrosine kinases. See, e.g., Larner, et al. (1993) Science 261:1730-1733; and Lehmann, et al. (1994) J. Immunol. 153:165-172; each of which is incorporated by reference.

IX. Ligands: Agonists and Antagonists

- 19 -

The blocking of physiological response to IL-10-like peptides may result from the inhibition of binding of the ligand to the receptor, likely through competitive inhibition. Thus, in vitro assays of the present invention will often use isolated membranes from cells expressing a different activating receptor or fragments attached to solid phase substrates. These assays will also allow for the diagnostic determination of the effects of either binding segment mutations and modifications, or ligand mutations and modifications, e.g., ligand analogs. See, e.g., USSN 08/110,683; USSN 08/011,066; USSN 07/989,792; each of which are incorporated by reference.

X. Kits

This invention also contemplates use of the different activating variant IL-10 receptors, peptides, and their fusion products in a variety of diagnostic kits and methods, e.g., for detecting the presence of a ligand in a sample, e.g., mIL-10, hIL-10, or vIL-10. See, e.g., USSN 08/110,683; USSN 08/011,066; USSN 07/989,792; U.S. Pat. No. 3,645,090; U.S. Pat. No. 3,940,475; Rattle, et al. (1984) Clin. Chem. 30(9):1457-1461; U.S. Pat. No. 4,659,678; and Rattle, et al. (1984) Clin. Chem. 30(9):1457-1461; each of which is incorporated by reference. One method for determining the concentration of IL-10 in a sample would typically comprise the steps of: expressing a transfected super-activating receptor on the surface of the host cell; contacting this cell with a sample containing the ligand, e.g., IL-10; and assaying for a biological effect, e.g., proliferation. The high sensitivity of the cells to a ligand can form the basis of a very sensitive assay.

In particular, since individuals who are more sensitive to lower levels of ligand may be more responsive to IL-10 treatment, diagnostic methods to phenotype potential target patients will be useful to evaluate and identify patients who may possess polymorphic variant from the "standard" IL-10 receptor sequence, and will respond to drug. Conversely, diagnosis of polymorphic variations may identify other subsets of patients who may be susceptible to other treatments, e.g., may exhibit lesser negative effects to ligand, or who will be not responsive to a proposed treatment. Thus, diagnosis of patients, including analysis of genotype, may become important in strategic decisions for treat-

- 20 -

ment.

A preferred aspect of the present invention relates to a kit for performing a method according to the present invention, i.e. for detecting a IL-10RA variant or for distinguishing said variant from standard IL-10RA comprising

- means for detecting, especially amplifying, nucleic acids encoding standard human IL-10 RA,
- means for detecting, especially amplifying, nucleic acids encoding a polypeptide variant according to the present invention,
- means for performing detection, especially amplification, of said nucleic acids and,
- optionally, means for detecting the amplified nucleic acids.

XI. Therapeutic Applications

This invention provides reagents with significant therapeutic or diagnostic value. Some polymorphic variant forms of IL-10 receptor, fragments thereof and antibodies thereto, along with compounds identified as having binding affinity to the IL-10 receptor, will be more or less susceptible to treatment relative to the standard IL-10RA. See, e.g., autoimmune conditions, septic and toxic shock conditions, and infectious conditions. See, e.g., USSN 08/110,683; USSN 08/011,066; USSN 07/989,792; Hsu, et al. (1992) Int'l. Immunol. 4:563-569; de Waal Malefyt, et al. (1991) J. Exp. Med. 174:1209-1220; Fiorentino, et al. (1991) J. Immunol. 147:3815-3822; Ishida, et al. (1992) J. Exp. Med. 175:1213-1220; Harada, et al. (1992) J. Biol. Chem. 267:22752-22758; Gilman, et al. (eds.) (1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 9th ed., Pergamon Press; Remington's Pharmaceutical Sciences, 17th ed. (1992), Mack Publishing Co., Easton, Penn.; and The Merck Index, Merck & Co., Rahway, New Jersey; each of which is incorporated by reference.

XII. Additional Receptor Subunits

Various approaches would be useful for screening for accessory subunits of the IL-10 receptor. These approaches include both physical affinity methods, and activity screening. See, e.g., USSN 08/110,683; USSN 08/011,066; USSN 07/989,792; Kitamura, et al. (1991) Cell 66:1165-1174; and Hara, et al. (1992)

- 21 -

EMBO J. 11:1875-1884; each of which is incorporated by reference. The IL-10 receptor subunit beta (IL-10RB) has been identified. See Kotenko, et al. (1997) EMBO J. 16:5894-5903; and Spencer, et al. (1998) J. Exp. Med. 187:571-578; each of which is incorporated herein by reference.

The scope of this invention is best understood with reference to the following examples, which are not intended to limit the invention to specific embodiments exemplified.

EXPERIMENTAL

EXAMPLE 1: General Methods

Some of the standard methods are described or referenced, e.g., in Maniatis, et al. (1982) Molecular Cloning, A Laboratory Manual Cold Spring Harbor Laboratory, Cold Spring Harbor Press; Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed.), vols. 1-3, CSH Press, NY; Ausubel, et al., Biology, Greene Publishing Associates, Brooklyn, NY; or Ausubel, et al. (1987 and Supplements) Current Protocols in Molecular Biology Greene/Wiley, New York; Dieffenbach, et al (1995) PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview N.Y.; all of which are each incorporated herein by reference. Methods for protein purification include such methods as ammonium sulfate precipitation, column chromatography, electrophoresis, centrifugation, crystallization, and others. See, e.g., Ausubel, et al. (1987 and periodic supplements); Deutscher (1990) "Guide to Protein Purification" in Methods in Enzymology vol. 182, and other volumes in this series; and manufacturer's literature on use of protein purification products, e.g., Pharmacia, Piscataway, N.J., or Bio-Rad, Richmond, CA; which are incorporated herein by reference. Combination with recombinant techniques allow fusion to appropriate segments, e.g., to a FLAG sequence or an equivalent which can be fused via a protease-removable sequence. See, e.g., Hochuli (1989) Chemische Industrie 12:69-70; Hochuli (1990) "Purification of Recombinant Proteins with Metal Chelate Absorbent" in Setlow (ed.) Genetic Engineering, Principle and Methods 12:87-98, Plenum Press, N.Y.; and Crowe, et al. (1992) QIAexpress: The High Level Expression & Protein Purification System QUIAGEN, Inc., Chatsworth, CA: which are incorporated herein by reference.

- 22 -

Cell lines and tissue culture, fluorescence activated cell sorting (FACS), cytokines and antibodies, binding assays and Scatchard analysis, construction of deletion mutants, variants, IL-10 internalization, proliferation assays, DNA binding assays, and tyrosine phosphorylation studies are described, e.g., in Moore, et al., US Pat. 5,716,804.

IL-10RA variant expression vector constructs

The coding sequence of the IL-10RA cDNA was obtained by the 5'-RACE method from different individuals. These were reamplified with modified primers:

(IL-10R-EcoRV (SEQ ID NO: 6):

5'-CGATATCAGGATGCTGCCGTGCCTCGTAG-3' and

IL-10R-EcoRI (SEQ ID NO: 7):

5'-GGAATTCTCTCAGCCCGAGTCACTCAC-3', (harbouring nt59-nt1810 according to Seq ID No: 40)

for subsequent cloning. Amplicons were digested with the Eco-RV and Eco-RI and subcloned after gel purification in the expression vector pIRES-puro (Clontech Laboratories, Palo Alto, CA). Plasmids generated by this method were digested with several restriction enzymes to confirm the proper orientation and ligation of the inserts. The expression plasmids carrying the different IL-10RA haplotypes were designated for wildtype: pIRESpuro-10R1/3 and for the variant IL-10RA G351R: pIRESpuro-10R2/11. The presence of the different IL-10RA haplotypes was confirmed by Bidirectional PCR Amplification of Specific Alleles (BiPASA). To exclude the presence of an another PCR-induced mutation in insert DNA, both plasmids are subjected to dideoxy sequencing. Similar primers can be developed for other variant forms, using flanking sequences, from the coding or adjacent sequences.

Cells and Culture

Ba/F3, a murine pro-B cell line, were obtained from DSMZ (Braunschweig, Germany) and are maintained in RPMI 1640 medium supplemented with 10% fetal calf serum, 1% L-glutamine, 1 mM sodium pyruvate, 50 µg/ml gentamicin, and 10 ng/ml muIL-3.

TF-1, a human erythroleukemia cell line (DNAX, Palo Alto, CA) is grown, e.g., in RPMI 1640 supplemented with 10% fetal calf serum, 50 µg/ml gentamicin, and 1 µg/ml recombinant GM-CSF. Stable transfectants are generated, e.g., with 50 µg Nru-linearized

- 23 -

plasmid by electroporation (BaF3) at 400V and 960 μ F on a Bio-Rad gene pulser or with 10 μ g plasmid by cationic liposomal transfection (TF-1) with DMRIE (GIBCO-BRL, Gaithersburg). Each cell line is transfected with expression plasmids, e.g., pIRESpuro-10R1/3, pIRESpuro-10R2/11, and the empty vector pIRES-puro as negative control. Selection with 2 μ g/ml puromycin is begun 48 h after transfection. Puromycin-resistant hIL-10RA or hIL-10RA G351R expressing clones of BA/F3 and TF-1 are isolated, e.g., sorted twice by FACS based on their expression of hIL-10RA using 3F9 mAB (DNAX) and expanded in culture.

HepG2, a human hepatocellular carcinoma cell line, is maintained, e.g., in DMEM/F12 (Gibco-BRL) supplemented with 10% fetal calf serum and 50 μ g/ml gentamicin. Expression vectors of hIL-10RA are introduced into cells, e.g., by calcium phosphate-mediated transfection with Nru-linearized pIRESpuro-10R1/3, pIRESpuro-10R2/11, and pIRES-puro as control. Stable transfectants are selected, e.g., 48 hours after transfection with 1 μ g/ml puromycin. Puromycin-resistant clones of HepG2 are sorted twice by FACS based on their expression of hIL-10RA using 3F9 mAB and expanded in cell culture. Scatchard plot analysis is performed as described above to verify the surface expression/cell of the two different recombinant variants of IL-10RA on transfectants.

EBV immortalized lymphoblastoid cells are grown in RPMI 1640 with L-glutamine [2 mM] and 10% FCS after incubation of PBMC with B95-8 cell supernatants (ATCC: CRL 1612, as source of EBV).

Ligand binding studies

Transfectants BAF-10R1/3, BAF-10R2/11, and TF1-10R1/3, TF1-10R2/11 are tested for specific binding, e.g., using 125 I-labeled recombinant human IL-10 (DuPont-NEN, Boston, MA). 1×10^5 to 5×10^5 cells are centrifuged at 200 x g and washed with binding buffer (RPMI 1640 with 2% BSA and 0.02% sodium azide) and resuspended in 200 μ l binding buffer as triplicate samples with 4-530 pM 125 I-hIL-10 in the presence and absence of 100 nM hIL-10. After incubation at 4° C for 4 h in a rotary mixer, cells are pelleted through a 1:1 mixture of dibutyl- and dioctylphthalate oils in elongated centrifuge tubes, centrifuged at 400 x g for 5 min at 4° C and quick frozen in liquid nitrogen. The cell pellet and supernatant are assessed for bound and free 125 I cpm, respectively. Nonspecific binding cpm in samples containing unlabeled

- 24 -

hIL-10 is subtracted to obtain specific binding cpm. The dissociation constants (K_d) and the maximal concentration bound to cells (B_{max}) are calculated by Scatchard analysis of the saturating binding data using linear regression analysis and replotted, e.g., with the program SigmaPlot (SPSS Inc., Chicago).

Proliferation assay

The responsiveness of the transfectants BAF-10R1/3, BAF-10R2/11, TF1-10R1/3, TF1-10R2/11, and control transfectants to various doses of hIL-10 (0.01-100 ng/ml) is tested, e.g., in triplicates after 48 h of incubation by a colorimetric cell proliferation assay using tetrazolium salt XTT (Molecular Roche, Mannheim). In brief, transfectants of BA/F3 are washed twice with in supplemented RPMI 1640 that lack mIL-3. The cells are seeded, e.g., in 96 well at a density of 2×10^4 cells/well and rested for 3 h in the absence of mIL-3. The cells are then incubated with varying amounts of hIL-10 in a total volume of 150 μ l medium. To verify the specificity of hIL-10, the mAb 3F9 is included as an antagonist in some experiments.

Cell surface antigen expression

Cell surface expression of CD32/16 (Fc γ II/III receptor) is analyzed, e.g., as described by Ho, et al. (1995) Mol. Cell. Biol. 15:5043-5053. Briefly, cells grown in medium containing mIL-3, various concentrations of hIL-10 or both cytokines, are washed once with FACS buffer (HBSS, 3% FCS, 0.02% sodium azide), and then incubated with FITC-conjugated anti-murine CD16/32 mAb (Pharmingen, San Diego CA) or isotype control for 30 min on ice. Cells are washed twice with FACS buffer and analyzed with a FACS-can (Becton Dickinson).

Electrophoretic mobility shift assay

$2-3 \times 10^6$ cells (HepG2 transfected the recombinant variants of IL-10RA and control) are washed and treated with various doses (0.01-100 ng) of hIL-10 or medium for various times (7 min - 24 hours). Whole cell extracts are prepared, e.g., by solubilizing cells in whole extract buffer (0.1 % Triton X-100, 10 mM HEPES, pH 7.9, 2 mM EDTA, 1 mM EGTA, 400 mM KCl, 1 mM DTT, and 10% glycerol with 1 mM orthovanadate, 0.5 mM PMSF, and 5 μ g/ml each of pepstatin, leupeptin, and aprotinin) on ice for 30 min, which is

- 25 -

typically further cleared from insoluble material by centrifugation (10 000 x g) for 5 min at 4° C. Protein concentration of extracts is measured, e.g., by using the BCA-assay (Pierce) and 40 µg of cellular extract is incubated with, e.g., 25,000 cpm of an ³²P-end labeled double stranded oligonucleotide probe based on 18 bps of the GRR of the Fcgr1 gene (top strand (SEQ ID NO: 8): 5'-ATGTATTTCCCAGAAA-3'; bottom strand (SEQ ID NO: 9): 5'-CTTTTCTGGGAAATA-3') (Weber-Nordt, et al. (1996) J. Biol. Chem. 271:27954-27961) and the high affinity cis inducible element SIEm67: top strand (SEQ ID NO: 10): 5'-GATCTGATTACGGGAAATG-3' bottom strand (SEQ ID NO: 11): 5'-GATCCATTTCCCGTAATCA-3' (Sadowski, et al. (1993) Science 261:1739-1744). The incubation is performed, e.g., for 20 min at room temperature in 15 µl binding buffer (20 mM Hepes, pH 7.9, 40 mM KCl, 1 mM MgCl₂, 0.1 mM EGTA, 0.5 mM DTT, and 4% w/v Ficoll). The reaction mixture is separated, e.g., by electrophoresis on a 6% polyacrylamide gel in 0.25 x TBE for 3.5 h at 150 V. The gel is dried and analyzed by autoradiography. Specificity of the DNA binding complex is determined by incubating with a 100-fold excess of unlabeled GRR or SIEm67. To determine the identity of transcription factors present in the DNA binding complexes, supershift experiments are performed, e.g., by incubating extracts with antibodies specific for STAT-1 (anti-ISGF-3, Transduction Laboratories) or STAT-3 (C-20, Santa Cruz, Biotechnology) for 1 h at 4° C before the addition of the radiolabeled probes.

Phosphotyrosine specific Western blot analysis

Transfectants of HepG2 are treated with various doses of rhIL-10 (0.01-100 ng/ml) for various times (7 min to 24 hours) and lysed in a buffer containing, e.g., 50 mM Tris, pH 7.4, 150 mM NaCl, 30 mM NaPPi, 50 mM NaF, 2 mM EDTA, 1% Triton X-100, 0.5 mM PMSF, 1 mM sodium vanadate, and 5 µg/ml each of pepstatin, leupeptin, and aprotinin. After 15 min incubation on ice, the extracts are cleared, e.g., by centrifugation (at 15,000 rpm, 4° C for 8 min) and concentration of proteins determined, e.g., by the BCA-assay (Pierce). Equal amounts of proteins are resolved by 10% SDS/PAGE and transferred to PVDF membranes (Immobilon-P, Millipore, Bedford, MA). Membranes are probed with specific anti-phosphotyrosine Abs against STAT1 [Phospho-Stat1(Tyr701)], STAT3 [Phospho-STAT3(Tyr705)], and anti-phosphoserine [Phospho-Stat3

- 26 -

(Ser727)] and then developed, e.g., using the enhanced chemiluminescence system (ECL Amersham). The IL-10-mediated activation of STAT5 is analyzed in BAF-10R1/3, BAF-10R2/11 and control. Western blots are performed with a specific anti-phosphotyrosine antibody against STAT5 (Phospho-STAT5). Antibodies listed above are available, e.g., from New England Biolabs.

Reporter gene analysis

The CRP promoter fragment of 219 bp is excised from the CRP(219)-CAT construct and cloned, e.g., in the pGL3-basic vector (Promega) by standard procedures. The resultant reporter vector is sequenced and designated CRP(219)-Luc.

Transfectants of HepG2 are cultured, e.g., in six-wells, transiently (by the calcium phosphate method) transfected with 4 µg of a 1:1 mixture of the reporter gene construct pCRP(219)-luc and as an internal normalization marker pSV-beta-galactosidase (Promega). 24 h after transfection, the subcultures are either untreated or treated with various doses of hIL-10 for further 24 hours. 5×10^6 cells of each BAF-10R1/3, BAF-10R2/11, and parental Ba/F3 are transiently transfected, e.g., by electroporation with 10 µg of a 1:1 mixture of pXM-PRL(105) and pSV-beta-galactosidase vector. Subcultures are treated with various doses of hIL-10 for a period of 48 h. After treatment cells are lysed with Promega reporter lysis buffer and luciferase determined by using the Luciferase assay system (Promega) with a luminometer (Berthold). To account for differences in transfection efficiency, the activity of beta-galactosidase is determined on luminometer by using the Galacto-Star assay system (Tropix).

TNF-inhibition studies

Peripheral venous blood, anticoagulated with heparin, is drawn from 15 individuals with different IL-10RA genotypes and zygosity. Monocytes are isolated, e.g., by Ficoll-Hypaque density centrifugation and adherence, and then suspended at a density of 1×10^6 cells/ml in RPMI 1640 medium (GIBCO-BRL), which is supplemented with 10% heat-inactivated FCS, and glutamine. Aliquots of (0.2 ml) in microtiter wells of this PBMC suspension are left untreated, or treated either with 1 µg/ml LPS alone or together with various doses of hIL-10 (0.1-100 ng/ml) for 24 h. TNF-alpha secreted in the cell supernatants is assayed.

- 27 -

EXAMPLE 2: Natural Polymorphisms

Targeted disruption of the interleukin-10 (IL-10) gene in mice causes chronic intestinal inflammation which is susceptible to therapy with recombinant IL-10. As a consequence, rhIL-10 was studied for treatment of human inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis. A minority of patients showed a clinical improvement after administration of this cytokine. Nevertheless, in certain patients rhIL-10 induced complete endoscopic healing of ulcerated mucosa. This was most obvious in Crohn's disease when compared to a 0% response in the placebo treated control patients.

By searching for mutations in genes, which are involved in the IL-10 pathway and which could account for the favorable effect of rHuIL-10 in this distinct subgroup, a new mutation was identified in the cytoplasmic domain of the IL-10 receptor alpha chain. Additional polymorphic analysis identified a second site of variation.

IL-10RA genotype and response to rhIL-10

Seven Crohn's disease patients who had been treated with rhIL-10 (5-20 µg/kg per day for 4 weeks, sc) and had shown endoscopic improvement or healing (n=4) or no response (n=3) were chosen for analysis. PBMC's were isolated from each subject. After stimulation of PBMC with LPS, total RNA was extracted and subjected to cDNA synthesis. The entire coding sequence of the IL-10RA mRNA (=1737 bp) was sequenced after reverse transcription and rapid amplification of cDNA ends (5'-RACE) followed by PCR amplification of four overlapping segments on an automated sequencer (ABI 373, Perkin Elmer). In 8 out of 11 individuals a G to A transition at position 1051 was detected causing a substitution of glycine 351 to arginine (IL-10RA G351R). The data has also been confirmed by sequencing genomic DNA. The mutation is located in the cytoplasmic domain upstream from the tyrosine residues, Y446 and Y496 in an area (Aa 282-389) that, when deleted in mice (D282-389), leads to increased cell proliferation (Ho, et al., 1995). Interestingly, only Crohn's disease patients with this mutation (heterozygote or homozygote) showed a therapeutic response to rHuIL-10.

Two patients possessing the "standard" IL-10 receptor se-

- 28 -

quence only were not responsive to the administration of IL-10; three patients who were heterozygous with the described polymorphic G351R variation and "standard" were responsive, while one heterozygous patient was not responsive; and the one patient who exhibited homozygous variation was responsive to ligand administration.

Bi-directional PCR Amplification of Specific Alleles

For rapid detection of this mutation in larger cohorts, an allele specific PCR diagnosis was established, designated Bi-directional PCR Amplification of Specific Alleles (BiPASA). This method allowed distinguishing between the presence or absence and zygosity of the different IL-10RA genotypes in genomic DNA. The accuracy of this method was verified by a blinded comparison of BiPASA with cycle sequencing in 50 DNA samples. Both methods showed 100% identical results.

Detection of the different IL-10RA genotypes and zygosity by bi-directional PCR amplification of specific alleles (Bi-PASA):

To determine the different genotypes in the human IL-10RA gene two genetic test methods were developed. For each genetic variation in the coding sequence of the human interleukin-10 receptor alpha chain (IL-10RA) a separate test method was developed to detect the single-base changes and simultaneously distinguish between homozygotes and heterozygotes in one PCR reaction by utilizing a specific primer design and balanced concentration of primers with appropriate cycling conditions (Liu et al., 1997b)

The polymorphisms in the IL-10RA gene are typed by bi-directional PCR amplification of specific alleles (Bi-PASA) using 1-200 ng genomic DNA as template in each reaction. For each detection, four different primers (two outer primers designated as P and Q as well as 2 inner primer designated as A and B) were used in a single tube. PCR was performed using e.g. Taq DNA Polymerase (Promega) or AmpliTaq Gold (Applied Biosystems) with the buffers supplied from the manufacturer. The method can be easily adopted for high throughput population based analysis.

As an example Bi-Pasa can be performed under following cycling conditions using a thermal cycler (e.g. MJ Research; PTC 200):

- 29 -

Initial denaturation at 95 degree for 5 min

40 cycles with:

Denaturation: 95 degree for 45 sec

Primer annealing at 58-60 degree for 30 sec

Primer extension at 72 degree for 45 sec

Followed by a final extension at 72 degree for 7 min

PCR products are separated by size using standard agarose or polyacrylamide gel electrophoresis and visualized by specific staining such ethidium bromide or by other methods, which are well known in art. The size and number of PCR products represents genotype of the IL-10RA of the analyzed DNA sample.

Figure 1. Separated PCR products represent the IL-10 receptor alpha genotypes

Size of PCR fragments Bi-PASA of IL-10RA-G351R:

Control fragment IL-10RPQ-351: 515 bp;

Wildtype fragment IL-10RAQ-351: 318 bp

Variant fragment IL-10RPB-351: 248 bp

Size of PCR fragments for Bi-PASA of IL-10RA-S159G

Control fragment IL-10RPQ-159: 464 bp

Wildtype fragment IL-10RAQ-159: 337 bp

Variant fragment IL-10RPB-159: 183 bp

Detection of the IL-10RA genetic variant IL10RA-S159G: the corresponding A-G substitution at nucleotide 536 is numbered according to the published IL-10RA cDNA sequence (Genbank entry: U00672 or UniGene: Hs.327).

Primer sequences for Bi-PASA of IL-10RA-S159G

Outer primers:

IL-10RP-159: 5'- TCAGCCCTCAAGTCTCATGGTATTC-3' (Seq.ID No.12)

IL-10RQ-159: 5'- TTGCTTCATCTACAAGGGCTCTGG-3' (Seq.ID No.13)

Allele specific inner primers:

IL-10RA-159: 5'-GGGCGGGGCGGCRAATGACACATATGAAA-3' (Seq.ID No.14)

IL-10RB-159: 5'-GGGCGGGGCGGAAGTGAAGATGCC-3' (Seq.ID No.15)

- 30 -

Note: Primer IL-10RA-159 is specially designed with R (R= A+G) to avoid interference with the G->A substitution found at nucleotide 520 in the IL-10RA cDNA (Tanaka et al., 1997).

Detection of IL-10RA genetic variant IL10RA-G351R:
The corresponding G-A substitution at nucleotide 1112 is numbered according to the published IL-10RA cDNA sequence.

Primer sequences for BiPASA of IL-10RA-G351R

Outer primers:

IL-10RP-351: 5'-CCCTTCATCTTCATCAGCCAGCGTC-3' (Seq.ID No.16);

IL-10RQ-351: 5'-CTCAGGTAACCCTGGAATGCCACAG-3' (Seq.ID No.17);

Allele specific inner primers:

IL-10RA-351: 5'-GCCGGGGGGGAGAACGCTGGGAAACG-3' (Seq.ID No.18);

IL-10RB-351: 5'-GGGGGCGGGCCACAGGGGGCTCCCT-3' (Seq.ID No.19);

PCR primers suitable for use in this aspect of the invention are not limited to SEQ IDs: 12-19 but encompass all pairs or sets of PCR primers suitable for selective amplification of the region of an IL-10RA gene of an animal (preferably a human), or for amplification of that part of this region in which the polymorphism of the invention is located.

Variation 1 (IL-10RA-S159G):

An A to G substitution in the coding sequence of the original human IL-10RA cDNA sequence at nucleotide 536 (Genbank entry: U00672 or UniGene Hs.327) causing an amino acid conversion from serine to glycine at AA 159 in the extracellular domain of the interleukin-10 receptor alpha chain precursor (578 aa, Swissprot: locus I10R_HUMAN, Accession: Q13651).

cDNA Sequence IL-10RA (Seq.ID No.20):

521-AATGACACAT ATGAAAGCAT CTTCAGTCAC TTCCGAGAGT-561

cDNA Sequence IL-10RA-S159G (Seq.ID No.21):

521-AATGACACAT ATGAAGGCAT CTTCAGTCAC TTCCGAGAGT-561

Protein Sequence IL-10RA: 153-ANDTYESIFSHFREY-167
(Seq.ID No.22)

Protein Sequence IL-10RA-S159G: 153-ANDTYEGIFSHFREY-167

- 31 -

(Seq.ID No.23)

Variation 2 (IL-10RA-G351R):

An G to A substitution in the coding sequence of the human IL-10RA cDNA sequence at nucleotide 1112 (Genbank entry: U00672 or UniGene Hs.327) causing an amino acid conversion from glycine to arginine at AA 351 in the intercellular domain of the interleukin-10 receptor alpha chain precursor (578 aa, Swissprot: locus I10R_HUMAN, Accession: Q13651).

cDNA Sequence IL-10RA:

1101-CGCTGGGAAA CGGGGAGCCC CCTGTGCTGG-1130 (Seq.ID No.24)

cDNA Sequence IL-10RA-G351R:

1101-CGCTGGGAAA CAGGGAGCCC CCTGTGCTGG-1130 (Seq.ID No.25)

Protein sequence IL-10RA: 341-HPQADRTLGNGEPPVLGDSC-360
(Seq.ID No.26)

Protein sequence IL-10RA-G351R: 341-HPQADRTLGNREPPVLGDSC-360
(Seq.ID No.27)

Frequency of IL-10RA G351R in the normal population:

One hundred twenty healthy individuals were recruited out of hospital employees and patients with gallstones, inguinal hernia, or routine screening for thyroid function. The mean age was 45.4 years (15-86 years) and 65% were female. BiPASA analysis of DNA samples showed that 11/120 (9.2%) were homozygous for the IL-10RA G351R, 46/120 (38.3%) were heterozygous, and 63/120 (52.5%) were homozygous for the IL-10RA wildtype. From the 240 chromosomes under investigation, the frequency of IL-10RA G351R was 29% vs. 71% wildtype. The "standard" allele is more frequent by a factor 2.43. IL-10RA G351R has to be regarded as single nucleotide polymorphism (SNP); other SNPs should exist and elucidation of their properties and functions would be well within the capabilities of the practitioner.

Frequency of IL-10RA S159G in the normal population:

BiPASA analysis of 99 control subjects showed that 1 (1%) sample was homozygous for IL-10RA-S159G, 24 (24%) were heterozy-

- 32 -

gous, and 74 (75%) were homozygous for the wildtype. From 198 chromosomes under investigation, the frequency of IL-10RA-S159G was 13.13% vs. 86.87% wildtype. The standard allele is more frequent by the factor 6.62. The IL-10RA-S159G has to be regarded as a SNP. The finding that IL-10RA-S159G changes IL-10 binding is supported by Reineke et al., 1998; Hoover et al., 1999; Zdanov et al., 1996; Zdanov et al., 1997; Walter and Nagabhushan, 1995.

EXAMPLE 3: Disease correlations

For the study of the biological significance of the IL-10 G351R, the following issues may be addressed.

Susceptibility to inflammatory bowel disease

Unrelated patients with Crohn's disease and patients with ulcerative colitis may be prospectively analyzed for their IL-10RA genotypes using BiPASA. Recruitment of patient's parents may be done by mail. DNA may be sampled, e.g., peripheral blood may be drawn from patients and their parents. Detailed analysis can be recorded, e.g., the location pattern of ulcerative colitis patients, the Vienna Classification of Crohn's disease, and the level of pANCA and pASCA in serum can be applied for subgroup analysis. The transmission disequilibrium test and chi square test can be used to evaluate the frequency of allelic transmission to affected offspring. Spielman and Ewens (1996) Am. J. Hum. Genet. 56:11-14.

Susceptibility to autoimmune disease

DNA samples from patients with SLE and rheumatoid arthritis can be evaluated. A DNA bank from such patients might be evaluated, alternatively new patients may be recruited. For example, patients may be selected according to whether they meet at least 4 criteria of the American College of Rheumatology for SLE. Samples can be grouped according to various criteria, e.g., organ involvement, damage index, activity index, and serologic profile (anti-DNA antibodies, ENA, complement deficiency, HLA-DR). Some samples of DNA from first degree relatives may also be analyzed.

Correlations to previous studies on IL-10 promoter polymorphisms in patients may be evaluated. Data may be compared to control subjects, e.g., from the same ethnicity.

Similar studies to determine correlation of medical condi-

- 33 -

tion with receptor polymorphism may be applied, e.g., to EBV associated lymphoproliferative disorders (post-transplant lymphoproliferative disease, Burkitt's lymphoma); chronic lymphatic leukemia; chronic graft-versus-host diseases; septic shock/meningococcal infection and patient survival; Type I diabetes; atopic dermatitis; IL-10 in Hepatitis C; autoimmune hepatitis; and others. See, e.g., Berkow (ed.) The Merck Manual of Diagnosis and Therapy, Merck & Co., Rahway, N.J.; Thorn, et al. Harrison's Principles of Internal Medicine McGraw-Hill, NY.

EXAMPLE 4: Mechanistic studies

To further elucidate functional differences between standard and IL-10RA polymorphic variants, additional in vitro studies are possible.

Induction of proliferation and surface antigen expression

Recent studies have shown that recombinant murine IL-10RA expressed in the IL-3-dependent murine pro-B-cell line Ba/F3 can transduce a proliferative signal in response to IL-10. Ho, et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90:11267-11271; and Ho, et al. (1995) Mol. Cell. Biol. 15:5043-5053. IL-10-induced growth leads to differentiation which becomes evident by formation of large clusters of cells and by induction or enhancement of several surface antigens, including CD32/16, CD2, LECAM-1, and heat stable antigen. Ba/F3 transfectants expressing membrane-proximal deletion mutants of mIL-10RA (D282-389, D282-414, and D282-458) displayed a 30 to 100 fold higher sensitivity to IL-10.

In addition to studies in the murine pro-B-cell line Ba/F3, the recombinant human IL-10R have been expressed in a human erythroleukemia cell line TF-1. hIL-10 can also induce a short term proliferative response in human TF-1 cells expressing recombinant hIL-10RA. Liu, et al. (1997) J. Immunol. 158:604-613. As the functional characterization of mIL-10RA has already been done in Ba/F3 (Ho, et al., 1995), this hIL-10RA polymorphic variant will be first studied in this cell line. Additional proliferation studies may be performed in human TF-1 cells to exclude human/mouse species differences in the engagement between IL-10RA and IL-10RB.

Differences in IL-10RA expression, ligand binding affinities and internalization between the "standard" (wild type) and poly-

- 34 -

morphic IL-10RA will be determined by Scatchard plot analysis. Studies with EBV immortalized lymphoblastoid cells from individuals with different IL-10RA genotype and zygosity may also be subjected to similar analysis.

Signaling through the JAK-STAT pathway

The mutation IL-10R G351R lies within the membrane-proximal region, which suggests a focus on the IL-10RA variants on the IL-10 mediated activation of the different STAT factors and their potential to activate transcription of reporter genes. In a recent article, receptor signaling of IL-10 was studied in comparison with IL-6 via the induction of transcription through IL-6 responsive elements in the HepG2 cell line stably transfected with hIL-10RA. Lai, et al. (1996) J. Biol. Chem. 271:13968-13975. Different IL-6 responsive reporter constructs have been tested and the IL-10-mediated induction in the pCRP(219)-CAT (219-bp of the human C-reactive protein promoter, Ganter, et al. (1989) EMBO J. 8: 3773-3779) exceeded the IL-6 effect by several fold. The capability of IL-10RA variants to activate the 219-bp CRP promoter construct can be analyzed, e.g., by a luciferase reporter gene construct. The IL-10-mediated activation of STAT5 can be examined in transfectants of Ba/F3 using a luciferase reporter gene construct which is under the control of the b-casein promoter as described previously. See Wehinger, et al. (1996) FEBS Lett. 394:365-370.

Inhibition of LPS-stimulated TNF-alpha production

Stimulation of monocytes with bacterial lipopolysaccharides (LPS) induces expression of multiple cytokines, including TNF-alpha, IL-1b, and IL-6. Furthermore, IL-10 feedback inhibits expression of TNF-alpha, IL-1b, and IL-6, thus providing an efficient autocrine mechanism for controlling proinflammatory cytokine production in monocytes. See, e.g., de Waal Malefyt, et al. (1991) J. Exp. Med. 174:1209-20; Wang, et al. (1994) J. Immunol. 153:811-816; Donnelly, et al. (1995) J. Immunol. 155:1420-1427; and Aste-Amezaga, et al. (1998) J. Immunol. 160:5936-5944. Treatment of monocytes in vitro with rhIL-10 starting 20 hours before to 1 hours after exposure to LPS have been demonstrated to inhibit the secretion of TNF-alpha.

To study the sensitivity between the different IL-10RA geno-

- 35 -

types, PBMCs will be isolated from individuals with different IL-10RA genotypes and treated with various concentrations of rhIL-10 and LPS. Accumulation of TNF-alpha in the supernatant will be determined and the inhibition of LPS-induced TNF-alpha production in response to various doses of rhIL-10 will be plotted in percent of control (no rhIL-10).

Detection of the different IL-10RA genotypes and zygosity by bidirectional PCR amplification of specific alleles (Bi-PASA):

The exploration of the relationship between genome variation (SNPs) and complex phenotypes (common disease) is of clinical importance. A principal strategy is based upon large-scale analysis of intragenic SNPs in common disorders, resulting in the development of a number of internationally recognized tools and research strategies. SNPs, which are small alterations in DNA that vary from person to person, are expected to serve as genetic markers of predisposition to disease and may pave the way for the development of novel diagnostics and drugs tailored to an individual's genetic profile.

To determine the different genotypes in the human IL-10RA gene two genetic test methods were developed. For each genetic variation in the coding sequence of the human interleukin-10 receptor alpha chain (IL-10RA) a separate test method was developed to detect the single-base changes and simultaneously distinguish between homozygotes and heterozygotes in one PCR reaction by utilizing a specific primer design and balanced concentration of primers with appropriate cycling conditions (Overlapping PCR for bidirectional PCR amplification of specific alleles: a rapid one-tube method for simultaneously differentiating homozygotes and heterozygotes. Liu-Q; Thorland-EC; Heit-JA; Sommer-SS Genome-Res. 1997 Apr; 7(4): 389-98).

Detection of IL-10RA genetic variant IL10RA-G351R the corresponding G-A substitution at nucleotide number 1112 according to the published IL-10RA cDNA sequence (Genbank entry :U00672 or UniGene: Hs.327).

Primer sequences for genotyping of IL-10RA-G351R, artificial GC-clamps are underlined:

outer primers:

- 36 -

IL-10RP-351: 5'-CCCTTCATCTTCATCAGCCAGCGTC-3' (Seq.ID No.16);

IL-10RQ-351: 5'-CTCAGGTAACCCTGGAATGCCACAG-3' (Seq.ID No.17);

allele specific inner primers:

IL-10RA-351: 5'-GCCGGGGGGGAGAACGCTGGGAAACG-3' (Seq.ID No.18);

IL-10RB-351: 5'-GGGGGCGGGCCACAGGGGGCTCCCT-3' (Seq.ID No.19);

PCR primers suitable for use in this aspect of the invention are not limited to SEQ IDs (specify above listed primers) but encompass all pairs or sets of PCR primers suitable for selective amplification of the region of an IL-10RA gene of an animal (preferably a human), or for amplification of that part of this region in which the polymorphism of the invention is located.

Detection of IL-10RA genetic variants IL10RA-S159G the corresponding A-G substitution at nucleotide number 536 according to the published IL-10RA cDNA sequence:

outer primers:

IL-10RP-159: 5'- TCAGCCCTCAAGTCTCATGGTATTC-3' (Seq.ID No.12)

IL-10RQ-159: 5'- TTGCTTCATCTACAAGGGCTCTGG-3' (Seq.ID No.13)

allele specific inner primers:

IL-10RA-159: 5'- GggcggggGCGCRAATGACACATATGAAA (Seq.ID No.14)

(Primer has adapted to avoid interference with the already published G->A substitution at nucleotide 520)

IL-10RB-159: 5'-GGGGCGGGGCGAAGTGAAGATGCC-3' (Seq.ID No.15)

Note : Primer IL-10RA-159 is specially designed with R (R= A+G) to avoid an interference with the G->A substitution found at nucleotide 520 in the IL-10RA cDNA (Detection of polymorphisms within the human IL10 receptor cDNA gene sequence by RT-PCR RFLP. Tanaka Y, Nakashima H, Otsuka T, Nemoto Y, Nihiro H, Yamaoka K, Ogami E, Arinobu Y, Tachida H, Imamura T, Niho Y. Immunogenetics. 1997;46(5):439-41).

Variation 1: An A to G substitution in the coding sequence of the original human IL-10RA cDNA sequence at nucleotide 536 (Genbank entry :U00672 or UniGene Hs.327) causing an amino acid conversion from serine to glycine at AA 159 in the extracellular

- 37 -

domain of the interleukin-10 receptor alpha chain precursor (578 aa, Swissprot: locus I10R_HUMAN, Acession: Q13651).

cDNA Sequence IL-10RA:

521-AATGACACATATGAAAGCATCTTCAGTCACTTCCGAGAGT-561 (Seq.ID No.20)

cDNA Sequence IL-10RA-S159G:

521-AATGACACATATGAAGGCATCTTCAGTCACTTCCGAGAGT-561 (Seq.ID No.21)

Protein Sequence IL-10RA: AA 159 from IL-10RA: ANDTYESIFSHFREY (Seq.ID No.22) change to ANDTYEGIFSHFREY (Seq.ID No.23)

Variation 2: An G to A substitution in the coding sequence of the human IL-10RA cDNA sequence at nucleotide 1112 (Genbank entry :U00672 or UniGene Hs.327) causing an amino acid conversion from glycine to arginine at aa 351 in the intercellular domain of the interleukin-10 receptor alpha chain precursor (578 aa, Swissprot: locus I10R_HUMAN, Acession: Q13651).

cDNA Sequence IL-10RA:

nt1101-CGCTGGGAAACGGGGAGCCCCCTGTGCTGG-nt1130 (Seq.ID No.24)

cDNA Sequence IL-10RA-G351R:

nt1101-CGCTGGGAAACAGGGAGCCCCCTGTGCTGG-nt1130 (Seq.ID No.25)

Protein sequence IL-10RA:

HPQADRTLGNGEPPVLGDSC

(Seq.ID No.26)

Protein sequence IL-10RA-G351R:

HPQADRTLGNREPPVLGDSC

(Seq.ID No.27)

PCR test methods for genotyping IL-10RA variants:

The polymorphisms in the IL-10RA gene were typed by PCR using 1ng - 200ng genomic DNA as template in each reaction e.g. in a total volume of 25 µl. For each detection method four different primers two outer primers designated as P and Q as well as 2 inner primer designated as A and B. PCR was performed using e.g. Taq DNA Polymerase (Promega) or AmpliTaq Gold (Applied Biosystems) with the buffers supplied from the manufacturer. Optimization strategies for multiplex PCR reactions are well known in art can be gener-

- 38 -

ally obtained by varying the ionic strength of the reaction buffer (increase or decrease of K⁺ concentration), concentration of Mg²⁺, dNTPs, primer design and the concentration of the individual primers and the use of cosolvents such DMSO, trehalose, glycerol or betaine (PCR-books).

A bidirectional PCR amplification of specific alleles (Bi-Pasa) was developed to screen genotypes of IL-10RA by using genomic DNA as template. The method can be easily adopted for high throughput population based analysis.

As an example Bi-Pasa can be performed under following cycling conditions using a thermal cycler (e.g. MJ Research; PTC 200 as well as other commercially available thermal cyclers):

initial denaturation at 95 degree for 5 min
40 cycles with:

denaturation: 95 degree for 45 sec

primer annealing at 58-60 degree for 30 sec

primer extension at 72 degree for 45 sec

followed by a final extension at 72 degree for 7 min

PCR products are separated by size using standard agarose or polyacrylamid gel electrophoresis and visualized by specific stainings such ethidium bromide or by other methods which are well known in art. The size and number of PCR products represents genotype of the IL-10RA of the analyzed DNA sample.

Figure 1. Separated PCR products represents the IL-10 receptor alpha genotypes

Size of PCR fragments Bi-Pasa of IL-10RA-G351R:

genomic control fragment 515 bp;

wildtype fragment IL-10RAQ 318 bp

variant fragment IL-10RPB: 248 bp

Size of PCR fragments for Bi-Pasa for detecting IL-10RA-S159G

genomic control fragment: 464 bp

wildtype fragment IL-10RAQ 337 bp

variant fragment IL-10RPB 183 bp

Frequency of IL-10RA S159G in the normal population:

- 39 -

BiPASA analysis of DNA samples showed that 1/99 (1.0 %) were homozygote for IL-10RA S159G , 24/99 were heterozygous, and 74/99 were homozygous in the wildtype form. From 198 chromosomes under investigation the the frequency of IL-10RA S159G was 13.13% vs. 86.87% wildtype. The standard allele is more frequent by the factor 6.62.

Sequence ID No.38 (genomic fragment to detect human IL-10RA-S159G with BiPASA)

464

DNA

mammal

```
TCAGCCCTCA AGTCTCATGG TATTCCCCCC CACCCCAACT CCATTTAGTG ACTCTGACAG      60
TTGGCAGTGT GAACCTAGAG ATCCACAATG GCTTCATCCT CGGGAAGATT CAGCTACCCA      120
GGCCCAAGAT GGCCCCCGCG AATGACACAT ATGAAAGCAT CTTCAGTCAC TTCCGAGAGT      180
ATGAGATTGC CATTGCAAG GTGCCGGGAA ACTTCACGGT ATGGGGTTCC CCAAGGCCCC      240
AGGGCCAGAA CTCCCTTGGC TTCCCTGTCC CCTGGGCTGG AAGCACCTT GTGTGCCATT      300
GGGAACTTTG CTTATGGA CTAAAGGGAGGG TCTGGGATGG TGGGTGGGCA GAGGAGGGAG      360
TAGAAACCAC CTCAGCCCTC AGAGCTATGC TCTTGTGAGA TGCTCCTCAA AGGAATTGCC      420
TACTAGGGCA ATTGGGCACC CCAGAGCCCT TGTAGATGAA GCAA                        464
```

Sequence ID No.39 (genomic fragment to detect human IL-10RA-G351R; " NOTE.: NO DIFFERENCE BETWEEN Cdna AND DNA in this fragment)

515

DNA

mammal

```
CCCTTCATCT TCATCAGCCA GCGTCCCTCC CCAGAGACCC AAGACACCAT CCACCCGCTT      60
GATGAGGAGG CCTTTTGA GGTGTCCCA GAGCTGAAGA ACTTGACCT GCACGGCAGC      120
ACAGACAGTG GCTTTGGCAG CACCAAGCCA TCCCTGCAGA CTGAAGAGCC CCAGTTCCTC      180
CTCCCTGACC CTCACCCCA GGCTGACAGA ACGCTGGGAA ACGGGGAGCC CCCTGTGCTG      240
GGGGACAGCT GCAGTAGTGG CAGCAGCAAT AGCACAGACA GCGGGATCTG CCTGCAGGAG      300
CCCAGCCTGA GCCCCAGCAC AGGGCCACC TGGGAGCAAC AGGTGGGGAG CAACAGCAGG      360
GGCCAGGATG ACAGTGGCAT TGA CTAGT CAAACTCTG AGGGCCGGGC TGGGGACACA      420
CAGGGTGGCT CGGCCTTGGG CCACCACAGT CCCCCGGAGC CTGAGGTGCC TGGGAAGAA      480
GACCCAGCTG CTGTGGCATT CCAGGGTTAC CTGAG                        515
```

Analysis of the splice site mutation

Peripheral blood mononuclear cells (PBMCs) from seven pa-

- 40 -

tients with Crohns disease and four healthy donors were isolated from EDTA-whole blood using Ficoll-Paque Plus separation gradient (Pharmacia Biotech) following manufacturer's guidelines. Total RNA from PBMCs was isolated using TRI-Reagent® (Molecular Research Center Inc.; Cincinnati, OH) according to manufacturer's instructions. Utilizing the 5'-Race system for rapid amplification of cDNA ends (Life Technologies Inc, Rockville, MD), one microgram of each RNA were reverse transcribed using the SuperScript II and oligodT(18) primer according to the manufacturers instructions. After purification and precipitation the cDNA-reaction was diluted in 50µl TE buffer. To analyze entire coding region of IL-10RA mRNA four different overlapping fragments were generated by PCR in separate reaction tubes using sequence specific primers. For amplification of the 5'-untranslated region of the IL-10RA the 5' Race abridged anchored primer from the 5'-Race system for rapid amplification of cDNA ends was used together with a sequence specific primer (see fragment 1). Aliquots of 5µl from the diluted cDNA reaction were amplified by PCR using 1x PCR buffer, Mg2+ and dNTP (all reagents from Promega, Madison, WI) and 10 pmol of each primer in a total volume of 50µl. To increase the yield and fidelity of PCR a 3:1 mixture of Taq-DNA Polymerase (Promega, Madison, WI) and Pfu Turbo DNA polymerase (Stratagene, La Jolla, CA) was used instead of Taq DNA polymerase alone as recommended by the instructions of the manufacturer.

cycling conditions were used for PCR:

initial denaturation at 95 degree for 45 sec

35 cycles with:

denaturation: 95 degree for 45 sec

primer annealing at 58 degree for 30 sec

primer extension at 72 degree for 45 sec

followed by a final extension at 72 degree for 7 min

Following primers were used for PCR amplification and cycle sequencing reaction.

Fragment 1:

5'-GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG-3' (Seq.ID No.28);

5'-GGCAATCTCATACTCTCGGAAG-3' (Seq.ID No.29)

- 41 -

Fragment 2:

5'-TCATCCTCGGGAAGATTCAG-3' (Seq.ID No.30);

5'-GTCCAAGTTCTTCAGCTCTGG-3' (Seq.ID No.31),

Fragment 3:

5'-TTCATCAGCCAGCGTCCCTC-3' (Seq.ID No.32);

5'-TGGTCTGCCTCAGGTAACCC-3' (Seq.ID No.33);

Fragment 4:

5'-CAGGGTTACCTGAGGCAGAC-3' (Seq.ID No.34);

5'-TGCCTCGTGCCTAACTTCTG-3' (Seq.ID No.35);

RT-PCR products were analyzed by standard agarose gel electrophoresis. Beside the expected PCR products an additional truncated PCR product appeared in fragment 1 in one out of ten analyzed. The truncated form was isolated from the agarose gel and subjected to cycle sequencing and analyzed on a automatic sequencer (ABI-Prism 310, Applied Biosystems, Foster City, CA). Additionally the coding sequence of the truncated IL-10RA cDNA of this individual was amplified with IL-10R-EcoRV (Seq ID No: 5) and IL-10R-EcoRI (Seq ID NO: 6) subcloned in the expression vector pIRES-puro und further analyzed by sequencing. Sequence analysis showed that 179 bp of the IL-10RA coding sequence were spliced out in the truncated form of human IL-10RA. This phenomena was further characterized by analyzing the genomic intron-exon boundaries based on the draft of the human genome sequence. The genomic localization of the human IL-10RA has already been mapped on chromosome 11q23.3. Taniyama, T.; et al (1995) Hum. Genet. 95: 99-101. Search on public genomic DNA databases such as Megablast at National Center of Biotechnology Information showed that the 179 bp of the skipped exon has 100% homology on accession: AP000665 Homo sapiens genomic DNA, chromosome 11q, clone:CMB9-46G18. Based on these homology two primers were designed to amplify by PCR a region which covers the exon-intron boundaries of the skipped exon sequence. The amplified PCR-product of 297 bp was purified with Qiaquick PCR purification kit (Qiagen, Hilden, Germany), and subjected to cycle sequencing reaction and analyzed on an automatic sequencer (ABI-Prism 310, Applied Biosystems, Foster City, CA). Sequence analysis of this region showed a G-to-A substitution in the acceptor splice site of the exon (GTGGATGAAG/GTGCTTTT change to GTGGATGAAA/GTGCTTTT) in the intron-exon boundary at position 255 of the genomic fragment of

- 42 -

IL-10RA. This single base substitution cause a splice site mutation which leads to an exon-skipping during the synthesis of IL-10RA mRNA. The mutation was found in a heterozygotic manner in one healthy donor. Further sequence analysis on 25 unrelated patients with Crohns disease in order to identify the causative mutations in affected individuals and to determine the prevalence of this splice site mutation were carried out. None of these patients were found to be carriers of the mutation. The predicted protein sequence of the truncated form of IL-10RA mRNA leads to only 94 amino acids. Thereby only the first 62 amino acids are processed in the same manner as in the wildtype followed by an altered protein sequence of 32 aminoacids and a stop codon. It can be assumed that an individual with an homozygotic form of this mutation lacks a functional IL-10 receptor complex and must have similar phenotype as can observed in IL-10 knock out mice. Kuhn, R., et al (1993). Cell 75: 263-74.

Primers to amplify and analyze the genomic exon-intorn boundary:

Intron-Exon-FW: 5'-GCCTCTTGCGTCTCCCTTAAAG-3' (Seq.ID No.36);

Intron-Exon-RV: 5'-GGGACTTCAGAGCCATGTTCTAAG-3' (Seq.ID No.37);

Sequence ID No.1 (human IL-10RA nucleic acid)

1737

DNA

homo sapiens

ATGCTGCCGT GCCTCGTAGT GCTGCTGGCG GCGCTCCTCA GCCTCCGTCT TGGCTCAGAC	60
GCTCATGGGA CAGAGCTGCC CAGCCCTCCG TCTGTGTGGT TTGAAGCAGA ATTTTTCAC	120
CACATCCTCC ACTGGACACC CATCCCAAAT CAGTCTGAAA GTACCTGCTA TGAAGTGGCG	180
CTCCTGAGGT ATGGAATAGA GTCCTGGAAC TCCATCTCCA ACTGTAGCCA GACCCTGTCC	240
TATGACCTTA CCGCAGTGAC CTTGGACCTG TACCACAGCA ATGGCTACCG GGCCAGAGTG	300
CGGGCTGTGG ACGGCAGCCG GCACTCCAAC TGGACCGTCA CCAACACCCG CTTCTCTGTG	360
GATGAAGTGA CTCTGACAGT TGGCAGTGTG AACCTAGAGA TCCACAATGG CTTTCATCTC	420
GGGAAGATTC AGCTACCCAG GCCCAAGATG GCCCCGCGA ATGACACATA TGAAAGCATC	480
TTCACTCACT TCCGAGAGTA TGAGATTGCC ATTCGCAAGG TGCCGGGAAA CTTACAGTTC	540
ACACACAAGA AAGTAAAACA TGAAAACCTC AGCCTCCTAA CCTCTGGAGA AGTGGGAGAG	600
TTCTGTGTCC AGGTGAAACC ATCTGTCGCT TCCCGAAGTA ACAAGGGGAT GTGGTCTAAA	660
GAGGAGTGCA TCTCCCTCAC CAGGCAGTAT TTCACCGTGA CCAACGTCAT CATCTTCTTT	720
GCCTTTGTCC TGCTGCTCTC CGGAGCCCTC GCCTACTGCC TGGCCCTCCA GCTGTATGTG	780

- 43 -

CGGCGCCGAA	AGAAGCTACC	CAGTGTCTCTG	CTCTTCAAGA	AGCCCAGCCC	CTTCATCTTC	840
ATCAGCCAGC	GTCCCTCCCC	AGAGACCCAA	GACACCATCC	ACCCGCTTGA	TGAGGAGGCC	900
TTTTTGAAGG	TGTCCCCAGA	GCTGAAGAAC	TTGGACCTGC	ACGGCAGCAC	AGACAGTGGC	960
TTTGGCAGCA	CCAAGCCATC	CCTGCAGACT	GAAGAGCCCC	AGTTCCTCCT	CCCTGACCCT	1020
CACCCCCAGG	CTGACAGAAC	GCTGGGAAAC	GGGGAGCCCC	CTGTGCTGGG	GGACAGCTGC	1080
AGTAGTGGCA	GCAGCAATAG	CACAGACAGC	GGGATCTGCC	TGCAGGAGCC	CAGCCTGAGC	1140
CCCAGCACAG	GGCCACCTG	GGAGCAACAG	GTGGGGAGCA	ACAGCAGGGG	CCAGGATGAC	1200
AGTGGCATTG	ACTTAGTTCA	AAACTCTGAG	GGCCGGGCTG	GGGACACACA	GGGTGGCTCG	1260
GCCTTGGGCC	ACCACAGTCC	CCCGGAGCCT	GAGGTGCCTG	GGGAAGAAGA	CCCAGCTGCT	1320
GTGGCATTCC	AGGGTTACCT	GAGGCAGACC	AGATGTGCTG	AAGAGAAGGC	AACCAAGACA	1380
GGCTGCCTGG	AGGAAGAATC	GCCCTTGACA	GATGGCCTTG	GCCCCAAATT	CGGGAGATGC	1440
CTGGTTGATG	AGGCAGGCTT	GCATCCACCA	GCCCTGGCCA	AGGGCTATTT	GAAACAGGAT	1500
CCTCTAGAAA	TGACTCTGGC	TTCCTCAGGG	GCCCCAACGG	GACAGTGGAA	CCAGCCCCT	1560
GAGGAATGGT	CACTCCTGGC	CTTGAGCAGC	TGCAGTGACC	TGGGAATATC	TGACTGGAGC	1620
TTTGCCCATG	ACCTTGCCCC	TCTAGGCTGT	GTGGCAGCCC	CAGGTGGTCT	CCTGGGCAGC	1680
TTTAACTCAG	ACCTGGTCAC	CCTGCCCTC	ATCTCTAGCC	TGCAGTCAAG	TGAGTGA	1737

Sequence ID No.2 (human IL-10RA amino acid)

578

PRT

homo sapiens

MLPCLVLLA	ALLSLRLGSD	AHGTELPSP	SVWFEEFFH	HILHWTPIP	QSESTCYEVA	60
LLRYGIESWN	SISNCSQTL	YDLTAVTLD	YHSNGYRAR	RAVDGSRHS	WTVTNTRFS	120
DEVTLTVGS	VNLEIHNGFI	LKGIQLPRPK	MAANDTYESI	FSHFREYEIA	IRKVPGNFTF	180
THKKVKHEN	FSLTSGEVGE	FCVQVKPSVA	SRSNKGMSK	EECISLTRQY	FTVTNVIIF	240
AFVLLLSGAL	AYCLALQLY	VRRKKLP	SVL LFKKPSPF	IF ISQRPSPET	Q DTIHLDEEA	300
FLKVSPELKN	LDLHGSTD	SG FGSTKPSL	QT EEPQFLLP	DP HPQADRTL	GN GEPPVLGD	360
SSGSSNSTDS	GICLQEPSL	S PSTGPTWE	QQ VGSNSRGQ	DD SGIDL	VQNSE GRAGDTQ	420
ALGHHSPP	PEP EVPG	EDPAA VAFQGY	L RQT R	CAEEKATKT	GCL	480
LVDEAGLHPP	ALAKGYLKQD	PLEMTLASSG	APTQWNQPT	EEWSLLALSS	CSDLGISDWS	540
FAHDLAPLGC	VAAPGGLLGS	FNSDLVTLPL	ISSLSSE			578

Sequence ID No.3 (genomic fragment to analyze the splice site mutation)

297

DNA

mammal

- 44 -

GCCTCTTGCG	TCTCCCTTAA	AGGAGGTAGG	ATTGAGCACA	AGCTCGTTTC	CAGTGCCTAA	60
CCTGGTATCT	CCTCAGGTAT	GGAATAGAGT	CCTGGAAGTC	CATCTCCAAC	TGTAGCCAGA	120
CCCTGTCCTA	TGACCTTACC	GCAGTGACCT	TGGACCTGTA	CCACAGCAAT	GGCTACCGGG	180
CCAGAGTGCG	GGCTGTGGAC	GGCAGCCGGC	ACTCCAAGTC	GACCGTCACC	AACACCCGCT	240
TCTCTGTGGA	TGAAGGTGCT	TTTCCTCCCT	TGACTTAGAA	CATGGCTCTG	AAGTCCC	297

Sequence ID No.4 (truncated human IL-10RA sequence)

DNA

1558

DNA

mammal

ATGCTGCCGT	GCCTCGTAGT	GCTGCTGGCG	GCCTCCTCA	GCCTCCGTCT	TGGCTCAGAC	60
GCTCATGGGA	CAGAGCTGCC	CAGCCCTCCG	TCTGTGTGGT	TTGAAGCAGA	ATTTTTCAC	120
CACATCCTCC	ACTGGACACC	CATCCCAAAT	CAGTCTGAAA	GTACCTGCTA	TGAAGTGGCG	180
CTCCTGAGTG	ACTCTGACAG	TTGGCAGTGT	GAACCTAGAG	ATCCACAATG	GCTTCATCCT	240
CGGGAAGATT	CAGCTACCCA	GGCCCAAGAT	GGCCCCCGCG	AATGACACAT	ATGAAAGCAT	300
CTTCAGTCAC	TTCCGAGAGT	ATGAGATTGC	CATTGCGAAG	GTGCCGGGAA	ACTTCACGTT	360
CACACACAAG	AAAGTAAAC	ATGAAAACCT	CAGCCTCCTA	ACCTCTGGAG	AAGTGGGAGA	420
GTTCTGTGTC	CAGGTGAAAC	CATCTGTGCG	TTCCCGAAGT	AACAAGGGGA	TGTGGTCTAA	480
AGAGGAGTGC	ATCTCCCTCA	CCAGGCAGTA	TTTCACCGTG	ACCAACGTCA	TCATCTTCTT	540
TGCCTTTGTC	CTGTGCTCT	CCGGAGCCCT	CGCCTACTGC	CTGGCCCTCC	AGCTGTATGT	600
GCGGCGCCGA	AAGAAGCTAC	CCAGTGTCTT	GCTCTTCAAG	AAGCCAGCC	CCTTCATCTT	660
CATCAGCCAG	CGTCCCTCCC	CAGAGACCCA	AGACACCATC	CACCCGCTTG	ATGAGGAGGC	720
CTTTTGAAG	GTGTCCCCAG	AGCTGAAGAA	CTTGACCTG	CACGGCAGCA	CAGACAGTGG	780
CTTTGGCAGC	ACCAAGCCAT	CCCTGCAGAC	TGAAGAGCCC	CAGTTCCTCC	TCCCTGACCC	840
TCACCCCCAG	GCTGACAGAA	CGCTGGGAAA	CGGGGAGCCC	CCTGTGCTGG	GGGACAGCTG	900
CAGTAGTGGC	AGCAGCAATA	GCACAGACAG	CGGGATCTGC	CTGCAGGAGC	CCAGCCTGAG	960
CCCCAGCACA	GGGCCCACCT	GGGAGCAACA	GGTGGGGAGC	AACAGCAGGG	GCCAGGATGA	1020
CAGTGGCATT	GACTTAGTTC	AAAACCTCTGA	GGGCCGGGCT	GGGGACACAC	AGGGTGGCTC	1080
GGCCTTGGGC	CACCACAGTC	CCCCGGAGCC	TGAGGTGCCT	GGGGAAGAAG	ACCCAGCTGC	1140
TGTGGCATTG	CAGGGTTACC	TGAGGCAGAC	CAGATGTGCT	GAAGAGAAGG	CAACCAAGAC	1200
AGGCTGCCTG	GAGGAAGAAT	CGCCCTTGAC	AGATGGCCTT	GGCCCCAAAT	TCGGGAGATG	1260
CCTGGTTGAT	GAGGCAGGCT	TGCATCCACC	AGCCCTGGCC	AAGGGCTATT	TGAAACAGGA	1320
TCCTCTAGAA	ATGACTCTGG	CTTCCTCAGG	GGCCCCAACG	GGACAGTGGA	ACCAGCCCAC	1380
TGAGGAATGG	TCACTCCTGG	CCTTGAGCAG	CTGCAGTGAC	CTGGGAATAT	CTGACTGGAG	1440
CTTTGCCCAT	GACCTTGCCC	CTCTAGGCTG	TGTGGCAGCC	CCAGGTGGTC	TCCTGGGCAG	1500
CTTTAACTCA	GACCTGGTCA	CCCTGCCCCCT	CATCTCTAGC	CTGCAGTCAA	GTGAGTGA	1558

- 45 -

Sequence ID No.5 (truncated human IL-10RA protein)

94

PRI

mammal

MLPCLVLLA ALLSLRLGSD AHGTELPSP SVWFEEFFH HILHWTPIP N QSESTCYEVA 60

LLSDSDSWQC EPRDPQWLHP REDSATQAQD GPRE 94

Sequence ID No.40 IL-10RA cDNA according to UniGene Cluster Hs.327 IL10RA and
Genbank entry : U00672

3632

DNA

mammal (homo sapiens)

AAAGAGCTGG	AGGCGCGCAG	GCCGGCTCCG	CTCCGGCCCC	GGACGATGCG	GCGCGCCCAG	60
GATGCTGCCG	TGCCTCGTAG	TGCTGCTGGC	GGCGCTCCTC	AGCCTCCGTC	TTGGCTCAGA	120
CGCTCATGGG	ACAGAGCTGC	CCAGCCCTCC	GTCTGTGTGG	TTTGAAGCAG	AATTTTTC	180
CCACATCCTC	CACTGGACAC	CCATCCCAAA	TCAGTCTGAA	AGTACCTGCT	ATGAAGTGGC	240
GCTCCTGAGG	TATGGAATAG	AGTCCTGGAA	CTCCATCTCC	AACTGTAGCC	AGACCCTGTC	300
CTATGACCTT	ACCGCAGTGA	CCTTGGACCT	GTACCACAGC	AATGGCTACC	GGGCCAGAGT	360
GCGGGCTGTG	GACGGCAGCC	GGCACTCCAA	CTGGACCGTC	ACCAACACCC	GCTTCTCTGT	420
GGATGAAGTG	ACTCTGACAG	TTGGCAGTGT	GAACCTAGAG	ATCCACAATG	GCTTCATCCT	480
CGGGAAGATT	CAGTACCCA	GGCCCAAGAT	GGCCCCCGCG	AATGACACAT	ATGAAAGCAT	540
CTTCAGTCAC	TTCCGAGAGT	ATGAGATTGC	CATTGCAAG	GTGCCGGGAA	ACTTCACGTT	600
CACACACAAG	AAAGTAAAAC	ATGAAAACCT	CAGCCTCCTA	ACCTCTGGAG	AAGTGGGAGA	660
GTTCTGTGTC	CAGGTGAAAC	CATCTGTGCG	TTCCCGAAGT	AACAAGGGGA	TGTGGTCTAA	720
AGAGGAGTGC	ATCTCCCTCA	CCAGGCAGTA	TTTCACCGTG	ACCAACGTCA	TCATCTTCTT	780
TGCCTTTGTC	CTGCTGCTCT	CCGGAGCCCT	CGCCTACTGC	CTGGCCCTCC	AGCTGTATGT	840
GCGGCGCCGA	AAGAAGCTAC	CCAGTGTCTT	GCTCTTCAAG	AAGCCCAGCC	CCTTCATCTT	900
CATCAGCCAG	CGTCCCTCCC	CAGAGACCCA	AGACACCATC	CACCCGCTTG	ATGAGGAGGC	960
CTTTTTGAAG	GTGTCCCCAG	AGCTGAAGAA	CTTGGACCTG	CACGGCAGCA	CAGACAGTGG	1020
CTTTGGCAGC	ACCAAGCCAT	CCCTGCAGAC	TGAAGAGCCC	CAGTTCCTCC	TCCCTGACCC	1080
TCACCCCCAG	GCTGACAGAA	CGCTGGGAAA	CGGGGAGCCC	CCTGTGCTGG	GGGACAGCTG	1140
CAGTAGTGGC	AGCAGCAATA	GCACAGACAG	CGGGATCTGC	CTGCAGGAGC	CCAGCCTGAG	1200
CCCCAGCACA	GGGCCCACCT	GGGAGCAACA	GGTGGGGAGC	AACAGCAGGG	GCCAGGATGA	1260
CAGTGGCATT	GACTTAGTTC	AAAACCTCTGA	GGGCCGGGCT	GGGGACACAC	AGGGTGGCTC	1320
GGCCTTGGGC	CACCACAGTC	CCCCGGAGCC	TGAGGTGCCT	GGGGAAGAAG	ACCCAGCTGC	1380
TGTGGCATT	CAGGGTTACC	TGAGGCAGAC	CAGATGTGCT	GAAGAGAAGG	CAACCAAGAC	1440
AGGCTGCCTG	GAGGAAGAAT	CGCCCTTGAC	AGATGGCCTT	GGCCCCAAAT	TCGGGAGATG	1500

- 46 -

CCTGGTTGAT	GAGGCAGGCT	TGCATCCACC	AGCCCTGGCC	AAGGGCTATT	TGAAACAGGA	1560
TCCTCTAGAA	ATGACTCTGG	CTTCCTCAGG	GGCCCCAACG	GGACAGTGGA	ACCAGCCCAC	1620
TGAGGAATGG	TCACTCCTGG	CCTTGAGCAG	CTGCAGTGAC	CTGGGAATAT	CTGACTGGAG	1680
CTTTGCCCCAT	GACCTTGCCC	CTCTAGGCTG	TGTGGCAGCC	CCAGGTGGTC	TCCTGGGCAG	1740
CTTTAACTCA	GACCTGGTCA	CCCTGCCCCCT	CATCTCTAGC	CTGCAGTCAA	GTGAGTGACT	1800
CGGGCTGAGA	GGCTGCTTTT	GATTTTAGCC	ATGCCTGCTC	CTCTGCCTGG	ACCAGGAGGA	1860
GGGCCCTGGG	GCAGAAGTTA	GGCACGAGGC	AGTCTGGGCA	CTTTTCTGCA	AGTCCACTGG	1920
GGCTGGCCCCA	GCCAGGCTGC	AGGGCTGGTC	AGGGTGTCTG	GGCAGGAGG	AGGCCAACTC	1980
ACTGAAC TAG	TGCAGGGTAT	GTGGGTGGCA	CTGACCTGTT	CTGTTGACTG	GGGCCCTGCA	2040
GACTCTGGCA	GAGCTGAGAA	GGGCAGGGAC	CTTCTCCCTC	CTAGGAACTC	TTTCCTGTAT	2100
CATAAAGGAT	TATTTGCTCA	GGGGAACCAT	GGGGCTTTCT	GGAGTTGTGG	TGAGGCCACC	2160
AGGCTGAAGT	CAGCTCAGAC	CCAGACCTCC	CTGCTTAGGC	CACTCGAGCA	TCAGAGCTTC	2220
CAGCAGGAGG	AAGGGCTGTA	GGAATGGAAG	CTTCAGGGCC	TTGCTGCTGG	GGTCATTTTTT	2280
AGGGGAAAAA	GGAGGATATG	ATGGTCACAT	GGGGAACCTC	CCCTCATCGG	GCCTCTGGGG	2340
CAGGAAGCTT	GTCAGTGAA	GATCTTAAGG	TATATATTTT	CTGGACACTC	AAACACATCA	2400
TAATGGATTTC	ACTGAGGGGA	GACAAAGGGA	GCCGAGACCC	TGGATGGGGC	TTCCAGCTCA	2460
GAACCCATCC	CTCTGGTGGG	TACCTCTGGC	ACCCATCTGC	AAATATCTCC	CTCTCTCCAA	2520
CAAATGGAGT	AGCATCCCCC	TGGGGCACTT	GCTGAGGCCA	AGCCACTCAC	ATCCTCACTT	2580
TGCTGCCCCA	CCATCTTGCT	GACAACTTCC	AGAGAAGCCA	TGGTTTTTTG	TATTGGTCAT	2640
AACTCAGCCC	TTTGGGCGGC	CTCTGGGCTT	GGGCACCAGC	TCATGCCAGC	CCCAGAGGGT	2700
CAGGGTTGGA	GGCCTGTGCT	TGTGTTTGCT	GCTAATGTCC	AGCTACAGAC	CCAGAGGATA	2760
AGCCACTGGG	CACTGGGCTG	GGGTCCCTGC	CTTGTTGGTG	TTCAGCTGTG	TGATTTTGGA	2820
CTAGCCACTT	GTCAGAGGGC	CTCAATCTCC	CATCTGTGAA	ATAAGGACTC	CACCTTTAGG	2880
GGACCCTCCA	TGTTTGCTGG	GTATTAGCCA	AGCTGGTCCT	GGGAGAATGC	AGATACTGTC	2940
CGTGGACTAC	CAAGCTGGCT	TGTTTCTTAT	GCCAGAGGCT	AACAGATCCA	ATGGGAGTCC	3000
ATGGTGTCAT	GCCAAGACAG	TATCAGACAC	AGCCCCAGAA	GGGGGCATTA	TGGGCCCTGC	3060
CTCCCCATAG	GCCATTTGGA	CTCTGCCTTC	AAACAAAGGC	AGTTCAGTCC	ACAGGCATGG	3120
AAGCTGTGAG	GGGACAGGCC	TGTGCGTGCC	ATCCAGAGTC	ATCTCAGCCC	TGCCTTTCTC	3180
TGGAGCATTC	TGAAAACAGA	TATTCTGGCC	CAGGGAATCC	AGCCATGACC	CCCACCCCTC	3240
TGCCAAAGTA	CTCTTAGGTG	CCAGTCTGGT	AACTGAACTC	CCTCTGGAGG	CAGGCTTGAG	3300
GGAGGATTCC	TCAGGGTTCC	CTTGAAAGCT	TTATTTATTT	ATTTTGTTCA	TTTATTTATT	3360
GGAGAGGCAG	CATTGCACAG	TGAAAGAATT	CTGGATATCT	CAGGAGCCCC	GAAATTCTAG	3420
CTCTGACTTT	GCTGTTTCCA	GTGGTATGAC	CTTGAGAGAAG	TCACTTATCC	TCTTGAGGCC	3480
TCAGTTTCCT	CATCTGCAGA	ATAATGACTG	ACTTGTCTAA	TTCATAGGGA	TGTGAGGTTT	3540
TGCTGAGGAA	ATGGGTATGA	ATGTGCCTTG	AACACAAAGC	TCTGTCAATA	AGTGATACAT	3600
GTTTTTTTATT	CCAATAAATT	GTCAAGACCA	CA			3632

All references cited herein are incorporated herein by ref-

- 47 -

erence to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.

Reference List

- Bertina, R.M., Koeleman, B.P., Koster, T., Rosendaal, F.R., Dirven, R.J., de Ronde, H., van der Velden, P.A., and Reitsma, P.H. (1994). Mutation in blood coagulation factor V associated with resistance to activated protein C. *Nature* 369, 64-67.
- Cargill, M., Altshuler, D., Ireland, J., Sklar, P., Ardlie, K., Patil, N., Shaw, N., Lane, C.R., Lim, E.P., Kalyanaraman, N., Nemesh, J., Ziaugra, L., Friedland, L., Rolfe, A., Warrington, J., Lipshutz, R., Daley, G.Q., and Lander, E.S. (1999). Characterization of single-nucleotide polymorphisms in coding regions of human genes. *Nat. Genet.* 22, 231-238.
- Cho, J.H., Nicolae, D.L., Gold, L.H., Fields, C.T., LaBuda, M.C., Rohal, P.M., Pickles, M.R., Qin, L., Fu, Y., Mann, J.S., Kirschner, B.S., Jabs, E.W., Weber, J., Hanauer, S.B., Bayless, T.M., and Brant, S.R. (1998). Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. *Proc. Natl. Acad. Sci. U. S. A* 95, 7502-7507.
- Darnell, J.E., Jr. (1997). STATs and gene regulation. *Science* 277, 1630-1635.
- de Waal, M., Yssel, H., Roncarolo, M.G., Spits, H., and de Vries, J.E. (1992). Interleukin-10. *Curr Opin Immunol* 4, 314-320.
- Dean, M., Carrington, M., Winkler, C., Huttley, G.A., Smith, M.W., Allikmets, R., Goedert, J.J., Buchbinder, S.P., Vittinghoff, E., Gomperts, E., Donfield, S., Vlahov, D., Kaslow, R., Saah, A., Rinaldo, C., Detels, R., and O'Brien, S.J. (1996). Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the *CCR5* structural gene. Hemophilia Growth and Development Study,

- 48 -

Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. *Science* 273, 1856-1862.

Donnelly, R.P., Dickensheets, H., and Finbloom, D.S. (1999). The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. *J. Interferon Cytokine Res.* 19, 563-573.

Eskdale, J. and Gallagher, G. (1995). A polymorphic dinucleotide repeat in the human IL-10 promoter. *Immunogenetics* 42, 444-445.

Eskdale, J., Gallagher, G., Verweij, C.L., Keijzers, V., Westendorp, R.G., and Huizinga, T.W. (1998). Interleukin 10 secretion in relation to human IL-10 locus haplotypes. *Proc Natl Acad Sci U S A* 95, 9465-9470.

Fedorak, R.N., Gangl, A., Elson, C.O., Rutgeerts, P., Schreiber, S., Wild, G., Hanauer, S.B., Kilian, A., Cohard, M., LeBEAUT, A., and Feagan, B. (2000). Recombinant Human Interleukin 10 in the Treatment of Patients With Mild to Moderately Active Crohn's Disease. *Gastroenterology* 119, 1473-1482.

Gasche, C., Bakos, S., Dejaco, C., Tillinger, W., Zakeri, S., and Reinisch, W. (2000a). IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease. *J. Clin. Immunol.* 20, 362-370.

Gasche, C., Scholmerich, J., Brynskov, J., D'Haens, G., Hanauer, S.B., Irvine, E.J., Jewell, D.P., Rachmilewitz, D., Sachar, D.B., Sandborn, W.J., and Sutherland, L.R. (2000b). A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. *Inflamm Bowel Dis* 6, 8-15.

Halushka, M.K., Fan, J.B., Bentley, K., Hsie, L., Shen, N., Weder, A., Cooper, R., Lipshutz, R., and Chakravarti, A. (1999). Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. *Nat. Genet.* 22, 239-247.

Hampe, J., Schreiber, S., Shaw, S.H., Lau, K.F., Bridger, S., Macpherson, A.J., Cardon, L.R., Sakul, H., Harris, T.J., Buckler, A.,

Hall, J., Stokkers, P., Van Deventer, S.J., Nurnberg, P., Mirza, M.M., Lee, J.C., Lennard-Jones, J.E., Mathew, C.G., and Curran, M.E.

(1999). A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. *Am. J. Hum. Genet.* 64, 808-816.

Ho, A.S., Liu, Y., Khan, T.A., Hsu, D.H., Bazan, J.F., and Moore, K.W.

- 49 -

- (1993). A receptor for interleukin 10 is related to interferon receptors. *Proc Natl Acad Sci U S A* 90, 11267-11271.
- Ho, A.S., Wei, S.H., Mui, A.L., Miyajima, A., and Moore, K.W. (1995). Functional regions of the mouse interleukin-10 receptor cytoplasmic domain. *Mol. Cell Biol.* 15, 5043-5053.
- Hoover, D.M., Schalk-Hihi, C., Chou, C.C., Menon, S., Wlodawer, A., and Zdanov, A. (1999). Purification of receptor complexes of interleukin-10 stoichiometry and the importance of deglycosylation in their crystallization. *Eur. J Biochem.* 262, 134-141.
- Hugot, J.P., Laurent-Puig, P., Gower-Rousseau, C., Olson, J.M., Lee, J.C., Beaugerie, L., Naom, I., Dupas, J.L., Van Gossum, A., Orholm, M., Bonaiti-Pellie, C., Weissenbach, J., Mathew, C.G., Lennard-Jones, J.E., Cortot, A., Colombel, J.F., and Thomas, G. (1996). Mapping of a susceptibility locus for Crohn's disease on chromosome 16. *Nature* 379, 821-823.
- Irizarry, K., Kustanovich, V., Li, C., Brown, N., Nelson, S., Wong, W., and Lee, C.J. (2000). Genome-wide analysis of single-nucleotide polymorphisms in human expressed sequences. *Nat. Genet.* 26, 233-236.
- Kotenko, S.V., Krause, C.D., Izotova, L.S., Pollack, B.P., Wu, W., and Pestka, S. (1997). Identification and functional characterization of a second chain of the interleukin-10 receptor complex. *EMBO J.* 16, 5894-5903.
- Kotenko, S.V., Saccani, S., Izotova, L.S., Mirochnitchenko, O.V., and Pestka, S. (2000). Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). *Proc. Natl. Acad. Sci. U. S. A* 97, 1695-1700.
- Kuhn, R., Lohler, J., Rennick, D., Rajewsky, K., and Muller, W. (1993). Interleukin-10-deficient mice develop chronic enterocolitis. *Cell* 75, 263-274.
- Liu, Q., Thorland, E.C., Heit, J.A., and Sommer, S.S. (1997b). Overlapping PCR for bidirectional PCR amplification of specific alleles: a rapid one-tube method for simultaneously differentiating homozygotes and heterozygotes. *Genome Res.* 7, 389-398.
- Liu, Y., de Waal, M., Briere, F., Parham, C., Bridon, J.M., Banchereau, J., Moore, K.W., and Xu, J. (1997a). The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. *J Immunol* 158, 604-613.
- Liu, Y., Wei, S.H., Ho, A.S., de Waal, M., and Moore, K.W. (1994). Expression cloning and characterization of a human IL-10 receptor.

- 50 -

J Immunol 152, 1821-1829.

Meraz,M.A., White,J.M., Sheehan,K.C., Bach,E.A., Rodig,S.J., Dighe,A.S., Kaplan,D.H., Riley,J.K., Greenlund,A.C., Campbell,D., Carver-Moore,K., DuBois,R.N., Clark,R., Aguet,M., and Schreiber,R.D. (1996). Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84, 431-442.

Modigliani,R., Mary,J.Y., Simon,J.F., Cortot,A., Soule,J.C., Gendre,J.P., and Rene,E. (1990). Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 98, 811-818.

Moore,K.W., O'Garra,A., de Waal,M., Vieira,P., and Mosmann,T.R. (1993). Interleukin-10. Annu Rev Immunol 11, 165-190.

Reineke,U., Sabat,R., Volk,H.D., and Schneider-Mergener,J. (1998). Mapping of the interleukin-10/interleukin-10 receptor combining site. Protein Sci. 7, 951-960.

Riley,J.K., Takeda,K., Akira,S., and Schreiber,R.D. (1999). Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem 274, 16513-16521.

Rioux,J.D., Silverberg,M.S., Daly,M.J., Steinhart,A.H., McLeod,R.S., Griffiths,A.M., Green,T., Brettin,T.S., Stone,V., Bull,S.B., Bitton,A., Williams,C.N., Greenberg,G.R., Cohen,Z., Lander,E.S., Hudson,T.J., and Siminovitch,K.A. (2000). Genomewide Search in Canadian Families with Inflammatory Bowel Disease Reveals Two Novel Susceptibility Loci. Am. J. Hum. Genet. 66, 1863-1870.

Rodig,S.J., Meraz,M.A., White,J.M., Lampe,P.A., Riley,J.K., Arthur,C.D., King,K.L., Sheehan,K.C., Yin,L., Pennica,D., Johnson,E.M.J., and Schreiber,R.D. (1998). Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93, 373-383.

Satsangi,J., Parkes,M., Louis,E., Hashimoto,L., Kato,N., Welsh,K., Terwilliger,J.D., Lathrop,G.M., Bell,J.I., and Jewell,D.P. (1996). Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 14, 199-202.

Saunders,A.M., Strittmatter,W.J., Schmechel,D., George-Hyslop,P.H., Pericak-Vance,M.A., Joo,S.H., Rosi,B.L.,

- Gusella, J.F., Crapper-MacLachlan, D.R., and Alberts, M.J. (1993). Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. *Neurology* 43, 1467-1472.
- Schreiber, S., Fedorak, R.N., Nielsen, O.H., Wild, G., Williams, C.N., Nikolaus, S., Jacyna, M., Lashner, B.A., Gangl, A., Rutgeerts, P., Isaacs, K., Van Deventer, S.J., Koningsberger, J.C., Cohard, M., LeBEAUT, A., and Hanauer, S.B. (2000). Safety and Efficacy of Recombinant Human Interleukin 10 in Chronic Active Crohn's Disease. *Gastroenterology* 119, 1461-1472.
- Schreiber, S., Heinig, T., Thiele, H.G., and Raedler, A. (1995). Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. *Gastroenterology* 108, 1434-1444.
- Spencer, S.D., Di Marco, F., Hooley, J., Pitts-Meek, S., Bauer, M., Ryan, A.M., Sordat, B., Gibbs, V.C., and Aguet, M. (1998). The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. *J. Exp. Med.* 187, 571-578.
- Stahl, N., Farruggella, T.J., Boulton, T.G., Zhong, Z., Darnell, J.E., Jr., and Yancopoulos, G.D. (1995). Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. *Science* 267, 1349-1353.
- Takeda, K., Clausen, B.E., Kaisho, T., Tsujimura, T., Terada, N., Forster, I., and Akira, S. (1999). Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. *Immunity* 10, 39-49.
- Tan, J.C., Indelicato, S.R., Narula, S.K., Zavodny, P.J., and Chou, C.C. (1993). Characterization of interleukin-10 receptors on human and mouse cells. *J. Biol. Chem.* 268, 21053-21059.
- Tanaka, Y., Nakashima, H., Otsuka, T., Nemoto, Y., Niino, H., Yamaoka, K., Ogami, E., Arinobu, Y., Tachida, H., Imamura, T., and Niho, Y. (1997). Detection of polymorphisms within the human IL10 receptor cDNA gene sequence by RT-PCR RFLP. *Immunogenetics* 46, 439-441.
- Ullrich, A. and Schlessinger, J. (1990). Signal transduction by receptors with tyrosine kinase activity. *Cell* 61, 203-212.
- Van Deventer, S.J., Elson, C.O., and Fedorak, R.N. (1997). Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. *Gastroenterology* 113, 383-389.
- Walter, M.R. and Nagabhushan, T.L. (1995). Crystal structure of in-

- 52 -

terleukin 10 reveals an interferon gamma-like fold. Biochemistry 34, 12118-12125.

Zdanov, A., Schalk-Hihi, C., Menon, S., Moore, K.W., and Wlodawer, A. (1997). Crystal structure of Epstein-Barr virus protein BCRF1, a homolog of cellular interleukin-10. J Mol. Biol. 268, 460-467.

Zdanov, A., Schalk-Hihi, C., and Wlodawer, A. (1996). Crystal structure of human interleukin-10 at 1.6 Å resolution and a model of a complex with its soluble receptor. Protein Sci. 5, 1955-1962.

- 53 -

WHAT IS CLAIMED IS:

1. An isolated or recombinant polypeptide comprising a sequence substitution at position gly351 and/or ser159 or from position leu62 of standard human IL-10 receptor subunit alpha (IL-10RA) and processed forms thereof.
2. The polypeptide of claim 1, wherein:
 - a) said substitution of gly is with a charged amino acid;
 - b) said substitution of ser is with an uncharged amino acid; or
 - c) said polypeptide effects at least a three fold change in signal from IL-10 binding.
3. The polypeptide of claim 2, wherein:
 - a) said substitution of gly is with arg;
 - b) said substitution of ser is with gly; or
 - c) said change in signal is an increase.
4. A method of making an antibody which can distinguish said IL-10RA polypeptide of any one of claims 1 to 3 from the corresponding polypeptide of standard human IL-10RA, comprising immunizing a mammal with said variant, thereby producing an antibody which recognizes said variant but not said standard IL-10RA.
5. A method of making a polypeptide variant of a polypeptide according to any one of claims 1 to 3, comprising expressing an isolated or recombinant nucleic acid encoding said variant polypeptide.
6. The isolated or recombinant nucleic acid of claim 5 encoding said variant polypeptide.
7. A cell transformed with said isolated nucleic acid of claim 6.
8. An isolated or recombinant IL-10RA polypeptide of at least 12 amino acids comprising at least three residues matching each side of and flanking a substitution of standard human IL-10RA at:

- 54 -

- a) position gly351 of Seq.ID No.2
- b) position ser159 of Seq.ID No.2; or
- c) position leu61 of Seq.ID No.5.

9. The isolated polypeptide of claim 8, wherein said:

- a) substitution of gly351 of standard human IL-10RA is a super-activating IL-10RA;
- b) substitution is G351R;
- c) polypeptide matches at least 5 residues on each side flanking gly351
- d) substitution is S159G;
- e) polypeptide matches at least 5 residues on each side flanking ser159; or
- f) substitution of IL-10RA effects at least a three fold difference in signal from IL-10 binding.

10. The polypeptide of claim 8 or 9, comprising a sequence of TLGNREPPV, DTYESIFSH or EVALLSDSD.

11. A method of making a polypeptide of any one of claims 8 to 10, comprising expressing a nucleic acid encoding said polypeptide.

12. An isolated or recombinant nucleic acid encoding a recombinant polypeptide of any one of claims 8 to 10.

13. The nucleic acid of claim 12, further encoding:

- a) the extracellular domain of IL-10RA; or
- b) C proximal sequence from G351 of IL-10RA.

14. A cell transformed with said nucleic acid of claim 12 or 13.

15. A method of making an antibody which can distinguish said IL-10RA polypeptide of any one of claims 8 to 10 from the corresponding polypeptide of standard human IL-10RA, comprising immunizing a mammal with said variant, thereby producing an antibody which can distinguish.

16. An antibody which can distinguish a polypeptide of

- 55 -

claim 10 from the corresponding polypeptide of standard human IL-10RA.

17. The antibody of claim 15 or 16, which is:

- a) a polyclonal antibody preparation;
- b) an immunoselected antibody preparation;
- c) an immunodepleted antibody preparation; or
- d) a monoclonal antibody.

18. A method allowing distinguishing:

- a) a nucleic acid encoding said variant of any one of claims 1 to 3 from one encoding standard human IL-10RA, said method comprising comparing said nucleic acid to one encoding said standard human IL-10RA; or
- b) a polypeptide variant of any one of claims 1 to 3 from standard human IL-10RA, said method comprising comparing said polypeptides.

19. The method of claim 18, wherein said comparing is:

- a) of nucleic acids, and said comparing is of:
 - i) PCR products; or
 - ii) restriction fragments; or
- b) of polypeptides, and said comparing is by:
 - i) immunoassay;
 - ii) evaluating cell responsiveness to IL-10.

20. The method of claim 18, wherein said distinguishing:

- a) allows therapeutic prognosis;
- b) provides differential functional information on said respective variants; or
- c) determines therapeutic treatment.


21. A kit for performing a method according to any one of claims 18 to 20 comprising

- means for detecting, especially amplifying, nucleic acids encoding standard human IL-10RA,
- means for detecting, especially amplifying, nucleic acids encoding a polypeptide according to any one of claims 1 to 3,
- means for performing detection, especially amplification, of said nucleic acids and,

- 56 -

- optionally, means for detecting the amplified nucleic acids.

Fig.1



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 September 2001 (07.09.2001)

PCT

(10) International Publication Number
WO 01/64713 A3

(51) International Patent Classification⁷: **C07K 14/715**,
C12N 15/19

(21) International Application Number: PCT/EP01/02296

(22) International Filing Date: 1 March 2001 (01.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/186,125 1 March 2000 (01.03.2000) US

(71) Applicants and

(72) Inventors: **GASCHE, Christoph** [AT/AT]; Babenberg-
ergasse 20, A-3400 Klosterneuburg (AT). **ZAKERI,**
Schaker, M. [AT/AT]; Einsiedlerplatz 10/19, A-1050
Vienna (AT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **REINISCH, Wal-**
ter [AT/AT]; Gumpoldskirchnerstrasse 26/3/17, A-2340
Mödling (AT).

(74) Agents: **SONN, Helmut** et al.; Riemergasse 14, A-1010
Vienna (AT).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
27 June 2002

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: MAMMALIAN INTERLEUKIN-10 (IL-10) RECEPTOR VARIANTS

	Homozygote Wildtype	Homozygote Variant	Heterozygotes
IL-10RPQ	_____	_____	_____
IL-10RAQ	_____		_____
IL-10RPB		_____	_____

(57) Abstract: Amino acid sequence and nucleic acid encoding variants of the IL-10 receptors, including polymorphisms. Uses of the receptor gene and polypeptides are disclosed, including means for screening for agonists and antagonists of the receptor ligands, for producing diagnostic or therapeutic reagents, and for producing antibodies. Therapeutic or diagnostic reagents and kits are also provided.



WO 01/64713 A3

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/715 C12N15/19

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 716 804 A (MOORE KEVIN W ET AL) 10 February 1998 (1998-02-10) ---	
A	US 5 985 828 A (HSU DI-HWEI ET AL) 16 November 1999 (1999-11-16) ---	
A	US 5 863 796 A (HSU DI-HWEI ET AL) 26 January 1999 (1999-01-26) -----	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

17 April 2002

Date of mailing of the international search report

29/04/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cervigni, S

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-21 (in part)

Polypeptide comprising a substitution at position gly351 of human Il-10 receptor subunit alpha. Its uses, antibodies raised against it and nucleic acid encoding therefor,

2. Claims: 1-21 (in part)

Polypeptide comprising a substitution at position ser159 of human Il-10 receptor subunit alpha. Its uses, antibodies raised against it and nucleic acid encoding therefor,

3. Claims: 1-21 (in part)

Polypeptide comprising a sequence substitution from position leu62 of human Il-10 receptor subunit alpha. Its uses, antibodies raised against it and nucleic acid encoding therefor,

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-21 (all partially)

Present claims 1-21 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, a polypeptide of at least 12 amino acids comprising at least three (or at least five) residues flanking a substitution of human IL-10RA or a polypeptide (of any length) comprising an (unspecified) sequence substitution starting from position 62 of IL-10RA cannot be considered a permissible generalisation which is fairly based on experimental evidence, that is, it is also not adequately supported by the description. Therefore, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for the general concept underlying the application and for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the IL-10RA specific variants G351R and/or S159G and extended to IL-10RA fragments disclosed in the description, corresponding to seq ID No. 23 and 27 as well as to seq ID No 5.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/02296

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5716804	A	10-02-1998	NONE	
US 5985828	A	16-11-1999	US 5789192 A	04-08-1998
			AT 177147 T	15-03-1999
			AU 5734094 A	04-07-1994
			CA 2151141 A1	23-06-1994
			CN 1090326 A ,B	03-08-1994
			DE 69323765 D1	08-04-1999
			DE 69323765 T2	22-07-1999
			DK 673420 T3	04-10-1999
			EP 0673420 A1	27-09-1995
			ES 2129622 T3	16-06-1999
			GR 3030038 T3	30-07-1999
			HK 1008830 A1	24-03-2000
			JP 7509613 T	26-10-1995
			JP 3135576 B2	19-02-2001
			WO 9413801 A1	23-06-1994
			US 5863796 A	26-01-1999
			ZA 9309243 A	09-06-1994
US 5863796	A	26-01-1999	US 5789192 A	04-08-1998
			AT 177147 T	15-03-1999
			AU 5734094 A	04-07-1994
			CA 2151141 A1	23-06-1994
			CN 1090326 A ,B	03-08-1994
			DE 69323765 D1	08-04-1999
			DE 69323765 T2	22-07-1999
			DK 673420 T3	04-10-1999
			EP 0673420 A1	27-09-1995
			ES 2129622 T3	16-06-1999
			GR 3030038 T3	30-07-1999
			HK 1008830 A1	24-03-2000
			JP 7509613 T	26-10-1995
			JP 3135576 B2	19-02-2001
			WO 9413801 A1	23-06-1994
			US 5985828 A	16-11-1999
			ZA 9309243 A	09-06-1994